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Dendritic mesoporous silica nanoparticles (DMSNs) are a new generation of porous materials that have
gained great attention compared to other mesoporous silicas due to attractive properties, including
straightforward synthesis methods, modular surface chemistry, high surface area, tunable pore size,
chemical inertness, particle size distribution, excellent biocompatibility, biodegradability, and high pore
volume compared with conventional mesoporous materials. The last years have witnessed a blooming
growth of the extensive utilization of DMSNs as an efﬁcient platform in a broad spectrum of biomedical
and industrial applications, such as catalysis, energy harvesting, biosensing, drug/gene delivery, imaging,
theranostics, and tissue engineering. DMSNs are considered great candidates for nanomedicine applications due to their ease of surface functionalization for targeted and controlled therapeutic delivery,
high therapeutic loading capacity, minimizing adverse effects, and enhancing biocompatibility. In this
review, we will extensively detail state-of-the-art studies on recent advances in synthesis methods,
structure, properties, and applications of DMSNs in the biomedical ﬁeld with an emphasis on the
different delivery routes, cargos, and targeting approaches and a wide range of therapeutic, diagnostic,
tissue engineering, vaccination applications and challenges and future implications of DMSNs as cuttingedge technology in medicine.
© 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Nanotechnology utilizes nanostructures and nanophases to
bridge the gap between biological and physical sciences. Nanoparticles (NPs) are synthesized for various applications such as
theranostics, targeted therapy, drug delivery, tissue engineering,
and regenerative medicine [1]. The most critical application for NPs
in the biomedical ﬁeld is drug delivery. NPs in the 10e400 nm
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mentioned above [15] for the ﬁnal controlled delivery of metallic
NPs, genes, vaccines, and catalysts [16e20]. The unique and ﬂexible
structure of DMSNs can therefore be leveraged to provide a
reproducible, facile, and precisely controlled porous structure for
diagnostics, therapeutics, and engineering applications [21e23].
The DMSNs may also be synthesized as organosilica NPs
(DMSONs) that possess three-dimensional nanochannels that
impart unique characteristics. Additionally, the incorporation of
organosilica NPs improves biocompatibility, biodegradability, and
hydrophobicity [24]. Similarly, Wang et al. synthesized dendritic
ﬁbrous nanoparticles (DFNPs) with central-radial nanochannels.
Several studies found DFNPs to possess structural superiorities that
enhance their candidature to serve as novel drug delivery platforms
and nanocatalysts [25].
Hao et al. recently reported a review article on the synthesis
procedures of DMSNs. The authors report elaborated methods of
micro-emulsion templating, organosilane co-condensation, and
spherical micelle self-aggregated assembly for synthesizing DMSNs
[26]. Thananukul et al. summarized stimuli-responsive gatekeepers
for porous nano-carrier drug delivery [27]. They brieﬂy discussed
the different templates and pore-forming agents like surfactants
and amphiphilic block polymers. In another review, Du and colleagues recently discussed the catalytic and biomedical applications of micro-/nano-dendritic silica particles [28].
In the present review, we discuss the different routes of synthesizing DMSNs, the relevant properties, and different delivery
routes that utilize complex targeting approaches to understand the
underlying chemistry that makes them unique. Further, the article
sheds light on the therapeutic applications of DMSNs using
different payloads. Finally, we discuss their use as diagnostic tools,
tissue engineering applications, safety considerations, and future
perspectives to enable researchers to brainstorm ideas to utilize
DMSNs for multimodal applications in an interdisciplinary
approach. Although previous review articles have discussed the
synthesis strategies of DMSNs and their potential chemical and
biomedical applications, the present review dives in-depth into the
synthesis strategies and lays a heavy emphasis on biomedical applications. This article spans various biomedical applications-gene
delivery, multiple cancer and tumor mitigating strategies, use of
DMSNs in vaccinations, tissue engineering, wound healing, and a
comprehensive discussion of the safety and toxicity of DMSNs.

range have been widely used as advantageous drug carriers since
they offer ﬂexibility in carrying many different payloads, can provide enhanced blood circulation and active cell-targeting. In addition, NPs also avoid the low bioavailability of certain drugs and
unfavorable pharmacokinetic parameters [2,3]. Several materials
are utilized as nanocarriers for drug delivery applications, including
chitosan, alginate, xanthan gum, cellulose, liposomes, polymeric
micelles, dendrimers, nanocrystal inorganic nanoparticles, metallic
nanoparticles, quantum dots, protein, and polysaccharide-based
nanoparticles [4].
Drugs can be directly conjugated to the NP surface using surface
chemistry or can be loaded within the NP's structure. A stimulus at
the target site can also be utilized to trigger the release of the drug.
In either of the above cases, it is essential to ensure that a therapeutic amount of drug is administered at the target site. To control
the amount of drug released, NPs can be conjugated with targeting
moieties that can take the advantage of ligand-receptor afﬁnity to
deliver the drug to the intended site [5]. The targeted receptor is
often a protein overexpressed on the cell's surface in a speciﬁc
disease condition. For instance, to deliver drugs to cancerous cells
ligands such as folate, epidermal growth factor, transferrin,
aptamers, antibodies, or antibody fragments were effectively utilized [4,6]. Several ligands have also been designed to deliver drugs
in other diseases such as inﬂammatory mediators, neuropeptides,
growth factors, and cytokines that can be used for atherosclerosis,
Crohn's disease, arthritis, spondylitis, and other auto-immune
disorders [7].
Among reported nanoparticles, dendritic mesoporous silica
nanoparticles (DMSN) have been developed and used as drug carriers for different applications [8]. As the name suggests, DMSNs
incorporate a mesoporous silica structure with radially symmetric,
highly ordered branched structures [9]. DMSNs have superior biological properties and higher surface area than classical mesoporous silica nanoparticles. Moreover, DMSNs offer easy surface
functionalization and have high speciﬁc pore volume that enables
the encapsulation of large payloads. Pore sizes in DMSNs range
from 2 to 50 nm and can be ﬁnely tuned for different applications
[10]. Since pore sizes are key determinants, several researchers
carried out systematic investigations to determine the pore sizes of
dendritic NPs. In one such study, Haozheng et al. [11] used rigid NPs
with tunable sizes as probes to detect the accessibility of the internal pore surface of dendritic porous NPs (DPSNs). Negatively
charged NPs of different diameters were used as probes. They reported that DPSNs with central-radial pore channels have greater
accessibility to the internal pore surface which affects the loading
capacity signiﬁcantly.
The Mobil Research and Development Corporation ﬁrst reported
the synthesis of mesoporous solids in 1992. These mesoporous
structures were synthesized from silicate gels using the liquid
crystal template mechanism [12]. A few years after, Cai and coworkers reported the synthesis of mesostructured silica with
tunable particle morphologies. In their studies, the NPs so obtained
were termed ‘radiolarian-like mesoporous silica nanoparticles.
These were the ﬁrst type of DMSNs reported [13,14]. In addition, the
authors reported a bimodal pore size distribution attributed to
micelles' dynamic self-assembly at the unstable oil-water interface
during the synthesis. Moreover, DMSNs can be easily synthesized to
have large internal pores with desired morphologies. Although in
principle, the internal structure of DMSNs helps extensive biomolecular loading, large internal channels can also lead to drug
leakage and thus reduce the amount of drug reaching the speciﬁc
target site during in vivo delivery. Therefore, surface modiﬁcation of
the DMSNs is an important issue to block the pores to prevent the
unwanted release of drugs. Recently, several surface modiﬁcations
have been successfully incorporated to tackle the phenomenon

2. DSMNS as multifunctional nanocarriers
2.1. Synthesis methods, structural characteristics, and chemical
properties
The development of ordered mesoporous materials MCM-41
[12] and SBA-15 [29], through a liquid crystal templating mechanism [30] pioneered the development of tunable porous silica
materials and directed the development of diverse sol-gel methods
to prepare ordered mesostructured with highly tunable porous
silica frameworks with the help of cationic, anionic, or non-ionic
surfactant as a template. The past three decades have shown
rapid growth in the development of mesoporous silica with various
topologies and architectures.
DMSNs present a unique structure that offers improved biological properties as a novel drug delivery platform able to encapsulate large payloads. The key advantages of DMSNs are mainly
determined by their characteristic dendritic porous structure, with
high surface area and tunable porosity [28]. Three main synthetic
strategies have been described in the literature for DMSNs, viz.
micro-emulsion templating (MET), organosilane assisted cocondensation (OAC), and spherical micelle self-aggregated assembly (SMSAA) (Fig. 1) [26]. In the MET approach, 3D-DMSNs are
2
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DMSNs have shown effectiveness for the immobilization and
encapsulation of enzymes, such as lipase [43,44], chloroperoxidase
[45], laccase [46], cytochrome monooxygenases family [47], and
glucosidases [48]. It is also applied in bio-catalysts with enhanced
catalytic properties, enzyme stabilization, and functionality in the
biomedical and industrial ﬁelds [49]. High protein loading capacity, highly accessible internal surface areas, and excellent
biocompatibility are the most important features of DMSNs for the
delivery of protein-based therapeutics [50]. DMSNs have also been
used for protein delivery by oral administration despite their
limited activity by degradation from gastrointestinal (GI) proteolytic enzymes and their permeation from barriers. An example is
the delivery of insulin by dendritic mesopores of DMSNs functionalized with thiol-groups [51]. Results showed that pH-related
degradation of this protein is signiﬁcantly inhibited, and the
transport of insulin successfully occurred. In the same way, D
MSNs could be used for the delivery of prodrugs, and are able to
tackle the physiological barriers against drug application,
including lack of speciﬁcity, low oral drug absorption, chemical
instability, toxicity, and poor patient acceptance (bad taste, odor,
and pain at the injection site) [52].
In addition, human gene therapy (GT) is rapidly gaining popularity and due to this ample attention is received for the development of novel gene carriers. Currently, silica NPs-based GT suffers
from low efﬁciency due to the passive-diffusion release of DNA and
RNA. This can be attributed to the strong electrostatic interactions
between negatively charged genes and positively charged NP surface. However, some of these problems can be avoided by utilizing
large-pore DMSNs for loading genetic content.
A more recent antitumoral approach is based on immunotherapy,
where the stimulation of the immune system was used for cancer
cell elimination. Conventional adjuvants like MF59, aluminum salts,
and ISA 206 are used for stimulating innate and secondary immunity. However, they can lead to toxicity-related safety concerns. For
this reason, nanoparticles are being evaluated. Among them, dendritic hierarchical mesostructured silica nanoparticles have shown
excellent properties for use as an adjuvant [19]. Uniform particle size
accompanied by large pore size showed high protein loading capacity (376 mg mg1). Moreover, in vivo study on guinea pigs
revealed no pathological abnormalities upon performing histology
[19]. Besides, DMSNs have shown their superiority for loading cytokines, such as tumor necrosis factor-alpha (TNF-a), for stimulating
the immune system, thus achieving effective anti-tumor efﬁcacy
while minimizing undesired side effects [53].
Cancer has several hallmarks including angiogenesis, mutations
in controlling genes, uncontrolled cell growth, resistance to the
natural cell death, cross-talks between cells, and activation of EMT
pathways. Due to this complexity, a single strategy like chemotherapy may not be effective to induce the anti-tumor effect
[54,55]. So, in the past decades, the results of numerous studies
showed promising outcomes of combinatorial methods such as
simultaneous delivery of two drugs, combination with genes or
with novel therapeutic methods like photodynamic therapy (PDT)
and photothermal therapy (PTT) [47]. These hybrid methods have
produced an excellent platform for blocking more than one
pathway in cancer development. DMSNs can play an important role
in the combinatory delivery of a small drug such as doxorubicin
with a big protein such as the interleukin-2 (IL-2) [56]. Additionally,
DMSNs can be conjugated with photosensitizers with monoclonal
antibodies (mAbs) for a dual chemo-PDT [57]. Finally, among the
different payloads, NPs can be loaded into the DMSNs. For example,
(Mn)-coupled dendritic mesoporous silicon nanoparticles also
containing indocyanine green (ICG) and glucose oxidase (GOD)
were successfully developed for tumor microenvironment (TME)
remodeling and cancerous cells eradication [58].

prepared in a heterogeneous oil-water biphasic system with the
silicate species in the oil phase and surfactant in the water phase
using an organic base as a catalyst [31]. This biphasic system allows
the reaction and facilitates assembly at the interface by altering or
adding reactants in each phase without interrupting the interface
(Fig. 1, a-d) [31]. Thus, this approach assisted in mesopore channel
growth and swelling through silicate oligomer polymerization and
condensation, forming new pore walls as a template (Fig. 1A, e-j)
[31]. This procedure successfully achieved several generations of
dendritic hierarchical mesostructures using a simple one-pot synthesis, in which pore size is tunable by changing hydrophobic solvents [31].
In the OAC approach, organotrialkoxysilane assisted by micelle/
precursor co-templating assembly was utilized to design and synthesize dendritic mesoporous organosilica nanoparticles (DMONs)
with uniform size, large nanopores, and small particle sizes [32].
This approach was exempliﬁed by Wu et al., utilizing bis[3-(triethoxysilyl)propyl] tetrasulﬁde (BTES) as a bissilylated organosilica
precursor to co-hydrolyze and co-condense organotrialkoxysilane
for the preparation of DMONs [32]. The thioether-bridged organic
group within BTES can be uniformly embedded with the framework (Fig. 1B a) as well as penetrate the hydrophobic domains of
surfactant micelles (Fig. 1B b) resulting in enlarged micellar structure and pore size of DMONs [32].
In the SMSAA approach [33], a dual template synergistically
controlled micelle self-aggregated model is utilized to form DMSNs
(Fig. 1C). Here, cationic and anionic surfactants are premixed,
resulting in mixed micelle aggregates (Fig. 1C i) [33]. Therefore, the
anionic micelles are not used as a template but act against negatively charged silicate oligomer adsorption. Furthermore, under
primary conditions, the hydrolysis and condensation of organotrialkoxysilane results in partially coated silica micelles (Fig. 2C ii)
[33]. To minimize the interface energy, these micelles fused to form
aggregates acting as a nucleus for the growth of the nanoparticles
(Fig. 1C iii). This partially covered mono -, bi-, and aggregated micelles help form DMSNs (Fig. 1C iv) [33].
The large pore size associated with the DMSNPs is helpful for
drug delivery applications, especially macromolecular payloads
[34]. As an example, Dai et al. [35] (Fig. 2) fabricated DMSNs with a
tunable pore size (~10 to ~35 nm) and high surface area prepared by
the microemulsion approach using different amounts of the cosolvent mixture. Furthermore, the authors also demonstrated that
guest nanoparticles such as copper sulﬁde (~10 nm), gold (~10 nm),
and iron oxide (~25 nm) could be incorporated into DMSNs [35].
Pore size is an essential consideration for the loading of small
molecules (drugs) or macromolecules (peptides, proteins, genes)
on DMSNPs.

2.2. Biomacromolecules delivery
The biomacromolecules such as peptides, sugars, antibodies,
proteins, and oligonucleotides [33,36,37], showed promising outcomes in treating common diseases. However, they introduce
instability in systemic circulation and are susceptible to immune
clearance and enzyme degradation [38,39], limiting their
bioavailability in the target organs. Therefore, encapsulating these
macromolecules in carries having a large pore size, such as DMSNs,
is a promising strategy to protect them from such biological bottlenecks. The commonly used mesoporous silica nanoparticles of
the MCM-41 type are not proper vehicles for encapsulating these
large molecules because of their narrow pore size [40,41]. However,
in mesoporous silica an increase in the diameter of pore channels
usually causes an increase in the whole NP size, which is inappropriate for drug delivery applications [42].
3
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Fig. 1. Synthesis and proposed mechanisms of DMSNPs formation through A) micro-emulsion templating [31], B) organosilane assisted co-condensation [32], and C) spherical
micelle self-aggregated assembly [33].

undergoes a structural deformation and subsequently triggers the
release of the loaded drug in a controlled manner [59e63]. The
endogenous stimuli-responsive carriers are advantageous as
changes in pH, redox potential, and speciﬁc enzyme concentration
can usually be found between the targeted and off-target tissue/
cells. On the other hand, exogenous stimuli-responsive carriers
have also been described using temperature, light, electric ﬁeld,
alternating magnetic ﬁeld (AMF), and ultrasound (Fig. 3) [64,65].
Table 1 lists a summary of various external and internal drug
release stimuli and their mechanism of action, pros, and cons.
Endogenous stimuli-responsive carriers have been widely
evaluated for triggered drug release applications. pH-responsive
carriers have been applied as drug delivery systems to speciﬁc organs (e.g., the vagina or the gastrointestinal tract) or intracellular
compartments (e.g., lysosomes or endosomes), or pathological
situations, such as inﬂammation or cancer. Constructing pHresponsive drug delivery systems is usually based on two approaches: the utilization of molecules with ionizable groups and
the utilization of pH-labile bonds in the structure of the pHresponsive carrier. For instance, amino DMSNs were synthesized

2.3. Stimuli-responsive delivery materials
As discussed above, the unique porous structure of DMSNs helps
biomacromolecule delivery. However, large channels can also lead
to important drug leakage and thus reduce the amount of cargo
reaching the speciﬁc target site during in vivo delivery. Therefore,
surface modiﬁcation of the DMSNs is a critical issue to block the
pores to prevent the unwanted release of drugs. Recently, several
surface modiﬁcations have been successfully incorporated to tackle
the phenomenon mentioned above [15] for the controlled delivery
of metallic NPs, genes, vaccines, and, catalysts [16e18,20,47]. The
unique and ﬂexible structure of DMSNs can be leveraged to provide
a reproducible, facile, and precisely controlled porous structure for
diagnostics, therapeutics, and engineering applications [21e23].
Stimuli-responsive carriers offer a more accurate spatiotemporal targeting and dosage-controlled drug release. This concept is
based on constructing a carrier that senses speciﬁc endogenous and
exogenous stimuli and responds dynamically (E. Aznar 2016) (A.
García Fern
andez, 2020). Depending on the stimulus, the smart
carrier is guided and accumulated into a speciﬁc organ or

Fig. 2. DMSNs are fabricated with different pore sizes, pore volumes, and BET surface using different amounts of the co-solvent mixture [35].
4

S. Malekmohammadi, R.U.R. Mohammed, H. Samadian et al.

Materials Today Chemistry 26 (2022) 101144

Fig. 3. Internal and external stimuli are applicable in active drug delivery systems.

linkage to synthesize DMSNs for co-delivery of DOX and shRNAexpressing plasmid (pDNA). The authors observed an acidic pHdependent drug and pDNA release. Besides, imidazole modiﬁcation of DMSN provided endosomal escape via a proton sponge
effect.
Most of the redox-responsive drug delivery systems are based
on the potential of glutathione (GSH) to cleave disulﬁde bonds,
taking advantage of the different GSH concentrations found in
intracellular (~2e10 mM) and extracellular (~2e10 mM) compartments, and in healthy tissues compared with tumor ones. Yang
et al. [70] used 1,4-bis (triethoxysilyl)-propane tetrasulﬁde (BTES)
as the precursor to homogeneously distribute disulﬁde groups into
a hybrid framework of DMSNs to synthesize GSH-dependent
degradable NPs. They observed that the NPs degradation in cancer cells was faster than in normal cells due to the higher GSH
concentration in the former. The authors also found a pore sizedependent degradation with a higher degradation in nanoparticles with larger pore sizes. Lu et al. [71] followed a similar
approach to synthesize a self-adjuvant and co-delivery system for
cancer immunotherapy. As above, BTES was used to provide a GSHdependent degradable behavior to the NPs and the system was
loaded with a toll-like receptor 9 (TLR9) and an antigen (ovalbumin). The authors also included PEI in the NPs to induce endosomal escape through the proton sponge effect. The synthesized
NPs could effectively escape from the endosome and deliver the
loaded cargos to antigen-presenting cells (APCs). In vivo studies
indicated that the administrated NPs reduced the intracellular GSH
level by disturbing ROS-GSH balance and subsequently enhanced
the proliferation of cytotoxic T lymphocytes (CTL) to suppress tumor growth. Despite the usability of DMSNs and similar NPs in drug
delivery systems, their long in vivo retention, difﬁcult degradability,
and toxicity causes severe shortcomings. One way to circumvent
this issue is by introducing disulﬁde bridges (as mentioned in the
previous study). Once the tumor cells take up the NPs with disulﬁde
bridges, the bridges are cleaved by a high concentration of glutathione and cause a release of cargo. Du et al. have comprehensively
summarized disulﬁde-bridged frameworks and their applications
in a recent review article [72].

as pH-responsive carriers for cyclometallated gold(III) delivery. The
amino groups formed weak hydrogen bond interactions with
cyclometallated gold(III). At acidic pH, the functional groups protonated and promoted the release of the loaded drug [66]. Curcumin (Cur) was also loaded into the pores of DMSN-decorated
reduced graphene oxide (rGO) and observed a signiﬁcant drug
release at acidic pH due to weakening the electrostatic interaction
between the drug and DMSNs. Cur is a herbal supplement, cosmetics ingredient, food ﬂavoring, and food coloring (bright yellow)
chemical agent produced by plants of the Curcuma longa species.
There are numerous reports, which have shown its anticancer,
antioxidant, anti-bacterial, and many different other functions of
this potent herbal extract in formulation with different nanocomplexes. The most important reason for using nanoformulation
of this magic extract is its low bioavailability, due to its negligible
hydrophilicity [67]. Fan et al. synthesized magnetic core-shell NPs
composed of cobalt ferrite@dendritic mesoporous silica shell and
doxorubicin (DOX) was loaded into the pores through hydrogen
bonds interactions between silanol groups (SieOH) of DMSNs and
carboxylic groups of DOX. The authors observed drug release under
acidic conditions caused by weakening hydrogen bonds and electrostatic interaction between the drug and the carrier, and
enhanced DOX's hydrophilicity due to its ammonium groups' protonation [68].
Huang et al. [69] synthesized pH-responsive DMSNs using
vinyltriethoxysilane as a precursor to synthesize vinyl modiﬁed
DMSNs. Subsequently, DOX was conjugated to the vinyl-modiﬁed
DMSNs through acid-liable hydrazone bonds (Scheme 1). Delivery studies demonstrated that the cumulative release of DOX in
acidic conditions (pH 5.3) was higher than in neutral conditions
(pH 7.4) due to the cleavage of the hydrazone moieties. Wang et al.
[70] synthesized pH-responsive DMSNs loaded with Cur for breast
cancer treatment. In this case, the authors modiﬁed DMSNs with
calcium hydroxide which was conjugated with curcumin through
chelating interactions with divalent calcium. The results showed
that Cur release reached up to 80% in 0.5 h under acidic conditions,
which was signiﬁcantly higher than that found in neutral conditions (35% release) after 12 h. Li et al. [69] used a Schiff-base
5
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Table 1
A summary of various external and internal drug release stimuli and their mechanism of action, pros, and cons [64,87e89].

External stimuli

ThermoResponsive
Systems

Ultrasound

Light-responsive
Systems

Electro-Responsive
Systems

Internal stimuli

Mechanism

Pros

Cons

High mobility of matrix
phase transition in
polymers above or
below deﬁned
temperatures
The thermal and
mechanical effects
generated by cavitation
phenomena or
radiation forces

Facile implementation
of active moieties
Facile formulation and
manufacturing

Instability of thermolabile drugs
Sensitive to environmental changes
Possible harmful effects on healthy cells

Signiﬁcant penetration
deep
Easily adjusted
Low cost
Local and focused heat
induction
Insensitive to
surrounding medium
Very precise
Easily tuned
Low cost
Spatiotemporal
targeting

Difﬁculty to target moving organs
Difﬁculty in exposing large zones
High reﬂection at the bone (60%) and air
(99%) interface
High absorption in bone
Expensive equipment for controlled
release

Pulsative release with
changes in electric
current
Spatiotemporal
targeting

Invasive implantation required
Required additional equipment for
external administration of stimulus
Hard to optimize the magnitude of
electric current
Poor penetration deep
Sensitive to the surrounding
environment
Embolism or toxicity through the
particles accumulation
Expensive and complex facilities
Large facilities

Photothermal
mechanism,
upconversion
mechanism, and twophoton activation
mechanism
Electrochemical
reductioneoxidation
and electric-ﬁelddriven movement of
charged molecules
Electrostatic
interactions variability

AMF-Responsive
Systems

Magnetic-guided
localization
Magnetic hyperthermia
Structural instability
through MNPs
ﬂuctuation

pH-Responsive
Systems

Ionization of basic or
acidic groups
Cleavage of acidsensitive bonds

Enzyme-responsive
Systems

site-speciﬁc enzymatic
cleavage

Redox-responsive
Systems

Disulﬁde bonds
cleavage by glutathione
(GSH)

Magnetic ﬁeld-induced
particles accumulation
Energy conversion with
an alternating magnetic
ﬁeld
Noninvasiveness
High tissue penetration
Spatiotemporal
targeting
Insensitive to the
surrounding
environment
Ease of implementation
pH difference in the
human body
Controlled drug release
Subcellular drug
delivery
Enzyme speciﬁcity
Protection of drugs in
blood circulation
Tumor-selective
accumulation
Controlled drug release
Improved
pharmacokinetic
Normal tissues Stability
Prompted response to a
high concentration of
GSH (usually a few
minutes to hours)
Cytoplasmic drug
delivery

Low tissue penetration (can be
improved by using NIR light)
For deep tissues: invasive
UV: harmful
Inconsistent responses to light

Not suitable in biosystems when adding
acid and base
Polymer-dependent toxicity
Poor conjugate bioactivity
Poor mechanical strength
Enzyme dysregulations in diseases
Heterogeneous spatial and temporal
patterns of enzyme activity
Substrates overlap for closely related
enzyme families
Complexity in the large-scale
production
Tumor cells heterogeneities
Complex biological environment

internalized into 4T1 cancer cells, escaped from the endo/lysosome compartments, and released the loaded drug into the
cytosol. Redox-responsive DMSNs have also been used for molecular imaging of the cellular trafﬁcking of NPs into cells. In this
frame, Du et al. [74] used an acetaldehyde-modiﬁed-cystine (AC)
linker, a GSH-responsive autoﬂuorescent reporter agent containing disulﬁde bonds to graft PEI on amino-functionalized DMSNs. In
this case, the reduction in ﬂuorescent signal intensity of AC under
interaction with cytosolic GSH revealed the internalization of the
vehicle. Increasing GSH concentration reduced the ﬂuorescent
intensity.

In another approach, Fei et al. [73] synthesized a smart redoxresponsive co-delivery system for a therapeutic model gene (Bcl-2
siRNA) and small-molecule anticancer drug (SN-38). The
cyclodextrin-conjugated PAMAM dendrimers were applied to
enhance the loading capacity of B-cell lymphoma-2 (Bcl-2) siRNA
and SN-38 through the electrostatic attraction and host-guest
interaction,
respectively. First,
the
authors conjugated
nitrophenyl-benzyl-carbonate, a ROS-responsive substance, on the
pore rims of DMSNs. Next, the dendrimers were attached to
DMSNs via a redox-sensitive ligand (azido ligand). The data indicated that the synthesized nanoplatform was successfully
6
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structural changes, including the photothermal effect, upconversion effect, and two-photon activation. The photothermal effect is
based on the conversion of light energy to heat that ﬁnally affects
temperature-responsive structures. The up-conversion effect is
based on the absorption of NIR light via speciﬁc materials and the
emission of UV light that then affect UV-sensitive systems. A similar
approach can be ﬂowed using two-photon activation [70,75,76]. In
the case of using ultrasound, the waves can not only trigger drug
release from speciﬁc carriers but also transient increase in vessel
permeability, providing both on-demand drug release and carrier
accumulation in the tumor [77,78].
Electric ﬁeld as a stimulus is usually applied as an external drug
release trigger. Different mechanisms are involved in the electrical
drug release stimulation, such as electrochemical oxidationreduction, changes in electrostatic interactions, and electric-ﬁelddriven displacement of charged moieties [78,79]. Magneticallyresponsive systems have shown promising results in both
magnetically guided carrier localization and magnetically triggered
drug release. Typically magnetic responsive systems incorporate a
magnetic agent, such as magnetite (Fe3O4) or maghemite (Fe2O3)
NPs [80,81]. Furthermore, thermal generation by MNPs through the
el and Brownian relaxation is another possible mechanism to
Ne
trigger drug release from thermo-responsive structures [82].
In these DMSNs, the stimuli-responsive ensembles are usually
attached to the surface serving as pore gatekeepers. Substances
such as Poly(N-isopropyl acrylamide) (PNIPAM), poly(N, N-diethyl
acrylamide) (PDEAAm), poly(N-vinyl caprolactam) (PVCL), and poly
[2-(dimethylamino)ethyl methacrylate] (PDMAEMA) for thermalresponsive material [83], azobenzene group, spiropyrane
merocyanine, thymine, and o-nitro benzyl for light-responsive
systems, polypyrrole, ethylene vinyl acetate, polyaniline, polythiophene, and polyethylene for electro-responsive materials
[79,84,85] and magnetic nanoparticles (MNPs) for magneticresponsive systems can be used. In an example [86], dendritic Silica/Titania mesoporous NPs loaded with curcumin were used for a
targeted synergetic chemo-sonodynamic therapy. PEI-FA was
attached to NPs through electrostatic interaction as a gatekeeper
and active targeting agent. In the synthesized system, the TiO2 layer
serves as the sonosensitizer agent generating free radicals, OH$ and
O
2 , under exposure to ultrasound. The generated free radicals cut
off the PEI gatekeeper and release the loaded Cur.
3. Administration and long-term circulation of DMSNs
Tailored nanostructures can be used as carriers and loaded/
conjugated/adsorbed with various small molecules, natural substances, and diagnosis agents for therapeutic and diagnostic applications [90,91]. Additionally, these nanocarriers can be
employed to deliver cargos through different routes, such as oral,
intravenous, intraperitoneal, intratumor, and transdermal routes
[92e98]. In this scenario, nanostructures should be appropriately
designed, fabricated, and modiﬁed concerning the intended
application and target cell/tissue/organ to be reached. Accordingly,
DMSNs offer tunable physicochemical properties with unique
characteristics [26,99]. After intravenous or intraperitoneal injection, a systemic distribution is observed in the bloodstream with
preferential accumulation on major target organs (liver, lung, kidneys, spleen), attributed to their high capacity to retain foreign
substances. Besides, DMSNs have also been applied locally in cancer
therapy through intratumoral injection, in skin treatments as
topical formulation [100], and for gastrointestinal delivery (GI) (see
Table 2) [101] (see Table 3).
Regarding systemic administration, the ability of nanoparticles
to accumulate in tumors has been reported. This phenomenon is
called passive targeting and it is related to the so-named enhanced

Scheme 1. Reaction scheme for the synthesis of pH-responsive DMSNs for the delivery
of DOX using acid-responsive hydrazone bonds. CTAB: Cetrimonium bromide, TEA:
Triethanolamine, TEOS: Tetraethoxysilane, MA: Maleic anhydride, VA: Vinyl acetate,
BPO: Benzoyl peroxide, RT: Room temperature.

Temperature-responsive carriers are usually based on the use of
thermal-responsive polymers used as gatekeepers. At a temperature higher than the critical temperature, the expansion or collapse
of polymer chains occurs due to disruption of the intramolecular
and intermolecular hydrophobic and electrostatic interactions of
the polymer chains.
Regarding external stimuli, light-responsive carriers have
shown promising results in on-demand drug delivery approaches.
In this case, light-responsive structures undergo structural changes
under interaction with light having speciﬁc wavelengths, such as
ultraviolet (UV), near-infra-red (NIR), or visible. Basically, three
different mechanisms have been proposed for light-induced
7
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Table 2
Examples of DMSNs in drug delivery applications and different delivery routes.
Chemical compound

Nanoparticle

Delivery routes

Effects

Omeprazole

DMSNs

Oral

Insulin

DMSNs

Oral

Exenatide

DMSNs

Oral

Gold (Au) and tantalum oxide (TaOx)

DMSNs

Injection- peritoneal cavity

Curcumin

DMSNs

Injection- peritoneal cavity

Paclitaxel

DMSNs

Injection- peritoneal cavity

Demethylcantharidin

DMSNs

Injection-intratumor

Indocyanine Green (ICG) and natural
glucose oxidase (GOD)

manganese etched DMSNs
(DMMnSiO3 NPs)

Injection-intratumor

Iron oxychloride (FeOCl)

(H-DMOS)

Injection- Intravenous

copper peroxide nanodots, chlorin e6 (Ce6),
and polyethylene glycol

UMNOCC

Injection- Intravenous

Doxorubicin (dox), all-trans retinoic acid (ATRA),
and interleukin-2 (IL-2)

DMSNs

Injection- Intravenous

5-HM, (5-hydroxymethylfurfural)

DMSNs

Direct

Increased solubility
and bioavailability,
passing through the
small intestine
[101]
Enhanced insulin
transport in the
intestine [51]
Improved loading
and decreased
burst release [102]
The enhanced
contrast agent
improved image
quality and
radiotherapy
treatment [103]
Increased
functionality and
bioavailability [70]
Improved drug
loading and
stability, decreased
cytotoxicity [104]
Improved
cancerous cell
growth control
without side effects
on healthy tissues
[105]
Controlled cell
proliferation, and
enhanced effect of
photothermal
therapy [106]
Inhibitory effect on
the growth of
cancerous cells
[107]
Notable tumor cell
apoptosis due to
simultaneous NO
generation and
Fenton-like
reaction [108]
Low systematic
toxicity, increased
tumor inhibitory
effect due to the
synergetic codelivery [56]
Increased
bioavailability
[100]

DMSNs with tunable size and surface characteristics can be
extravasated into tumor tissues through the EPR effect. The EPR
effect and its efﬁcacy for targeting applications can vary between
tumors and are highly dependent on intrinsic tumor biology factors
such as intratumor pressure, degree of lymphangiogenesis and
angiogenesis, the density of the stromal response, tumor cell
growth gradient, and the degree of perivascular tumor growth
(Fig. 4) [110,113]. Moreover, in a recent study by Sindhwani et al.
[114] the authors conﬁrmed the entry of the nanoparticles into the
tumors by an active process across endothelial cells rather than
through inter-endothelial gaps. The authors evaluated and
conﬁrmed their observation using different mouse models of human tumors, various imaging modalities, modeling, and simulation
approaches. These observations comprehensively explain the exact
mechanisms underlying the “passive” uptake of NPs.

permeation and retention (EPR) effect. It is well known that the
blood vessels and junctions in tumor tissue are distinct from
normal tissue due to prevailing inﬂammation/hypoxia conditions
[109,110]. During the fast growth and hypoxia, cancer cells secret
some angiogenesis factors such as vascular endothelial growth
factor (VEGF) and basic ﬁbroblast growth factor (bFGF) to mediate a
high level of angiogenesis. Accordingly, the newly formed vessels
are fenestrated and leaky. The endothelial cell junctions are loose,
enhancing permeability and extravasation of NPs with speciﬁc sizes
from the tumor vasculature into the tumor interstitium [111,112]. In
the same direction, impaired lymphatic drainage in tumor tissue
contributes to NPs retention. Although the exact size for the passive
targeting approach is not known, it is reported that the EPR effect is
beneﬁcial for the accumulation of macromolecules larger than
40 kDa or particles of diameter ~20e500 nm [109,110].
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Table 3
The common tumor marker, the overexpressing organs, and corresponding targeting agents.
Tumor marker

Overexpression in various tumors

Targeting agent

Ref

EGFR

Glioma (40e60%)
Colon (50%)
Head and neck (90e100%)
Lunge (45e80%)
Pancreas (22e60%)
Prostate (60e89%)
Breast Cancer (15e30% in invasive form)
Gastric Cancer (10e30%)
Esophageal Cancer (0e83%)
Ovarian Cancer (20e30%)
Endometrial Cancer (14e80%)
Lunge Cancers (20%)
Urothelial Bladder Carcinomas (23e80%)
Breast cancer
Vasculature endothelial cells in solid tumors

Cetuximab
scFv 425
Nanobody 8B6
Nanobody D10
EGF

[139]

Nanobody 2Rs15d scFv 4D5
Afﬁbody ABY-025
Pertuzumab
Trastuzumab (Herceptin)
Fam-trastuzumab-Deruxtecan

[140]

Epidermal growth factor receptor EGFR
RGD

[141]
[142]

1. Vascular Endothelial Growth Factor(VEGF)
2. Epidermal growth factor receptor (EGFR), vascular
endothelial growth factor receptor 2 (VEGFR2)
3. Multiple G-quadruplexes
Insulin and insulin-like growth factor (IGF)

[143e145]

HER2

HER3
Cellular adhesion molecules,
such as anb3-integrin
PDGFR b

IGF-1R
TfR (Transferrin receptor

PSMA
Carbohydrate moieties
Mesothelin
IL-13Ra2
FRa

FSHR
CD3

CD19

1. Endothelial cells
2. Tumor-associated stromal cells
3. Melanomas(50e60%)
breast cancer
prostate
Leukemia
Lung
Prostate
Ovarian
Liver
Colon
Breast
Brain
Prostate epithelium(94.1%)
Lung
Ovarian
Pancreatic cholangiocarcinoma
pulmonary ﬁbrosis
Ovarian 93%
Endometrial 90%
Renal 50%
Lunge 33%
Colorectal 22%
Breast 21%
vessel endothelial cells
prostate
Head
Neck
Colorectal
B cells in the bone marrow

[146]

HAIYPR (T7)peptide, PAMAM-PEG-T7/DOX
nanoparticles

[147]

In-DTPA-D2B-IRDye700DX
monoclonal antibodies
chimeric monoclonal antibody

[148]
[149]
[150]

Glioblastoma multiforme (GBM)
folate

[151,152]
[153]

follicle

[154]

HER2

[155]

Chimeric antigen receptors T cell

[156]

Pegylation is one of the most efﬁcient and well-established
approaches to modifying nanostructures' surfaces to mask them
from opsonization and extend their blood circulation time/half-life.
In this scenario, conjugated/adsorbed PEG polymer provides a
steric barrier on the nanostructure's surface. It repels blood plasma
proteins, cells, and other biomolecules [121,122]. Pegylation of silica
nanoparticles (NPs) has been extensively evaluated and conducted
using various methods. The electrostatic self-assembly (of PEG on
NPs is a straightforward and efﬁcient Pegylation process [123].
Thierry et al. [124] synthesized porous silica NPs physically decorated with polyethyleneimine (PEI)-PEG copolymer and reported
that the surface modiﬁcation increased colloidal stability in the
biological condition and reduced the nonspeciﬁc fouling via blood
serum proteins. Despite its simplicity and low cost, the physisorption methods suffer from low stability and vulnerability to
thermal, ionic strength, and pH of suspending media [125,126].
Apart from the physisorption, some chemical conjugation methods
are applicable for the Pegylation of DMSNs (Fig. 5), including PEGsilane, amine-NHS coupling, and thiol-carboxylate coupling, thiol-

The synthesized nanocarriers must have longer blood circulation times to accumulate at the intended site of action. The nonspeciﬁc uptake and fast clearance of intravenously injected nanocarriers by the opsonization/phagocytosis process and reticuloendothelial system (RES) cells are the most critical issues shortening
the blood circulation time/half-life [115,116]. The opsonization of
nanocarriers by the blood plasma proteins, mainly albumins,
complement proteins, immunoglobulins, ﬁbronectins, ﬁbrinogens,
and apolipoproteins, also limits their ability to accumulate at the
target site. In addition, nanocarriers can be visible to phagocytic
cells (e.g., neutrophils, monocytes, macrophages, and dendritic
cells) [117,118]. Nanostructure's surface properties, such as hydrophobicity, functional groups, and charge, have determinant roles in
the opsonization process. Hydrophilic and neutral surface charges
are more prone to escape opsonization compared to hydrophobic
and charged surfaces. Alternatively, the surface of nanostructures
can be modiﬁed with proper polymers, such as polyethylene glycols
(PEGs), dextran, and poly(N-(2-hydroxypropyl)methacrylamide)
(poly(HPMA)) [119,120].
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Fig. 4. Physiological properties of tumor tissue and vasculatures that can facilitate or prevent cancer drug delivery. Reproduced with permission from [114].

implementation of active targeting reduces the required injection
dose and it protects non-targeted normal tissues from the side
toxicity of nanoformulations [134,135]. Choosing a proper targeting
agent and the conjugation process are the most critical factors
determining the efﬁcacy of targeting. The candidate tumor marker
should be overexpressed explicitly in the target tumor, possess a
relatively high and speciﬁc afﬁnity to the conjugated/attached
ligand/targeting agent, and be accessible. Various targeting agents
made from carbohydrates (e.g., glucose, galactose, mannose, and
dextran), antibodies, nanobodies, cell surface receptors, vitamins
(e.g., vitamin D and folate), and aptamers have been evaluated for
active targeting applications [110,136e138].
In terms of the conjugation process, the conjugation must be
stable. In addition, the conjugation/attachment process should be
straightforward, facile, effective, and compatible with the targeting
agent. Broadly, the conjugation/attachment procedures targeting
agents on DMSNs are divided into physisorption and chemisorption
methods [157,158]. Physisorption methods are based on the physical
interactions between the targeting agent and DMSNs surfaces, such
as electrostatic interactions and hydrophobic interactions
[126,159,160]. Although they are partially straightforward and conducted in the mild experimental conditions, they suffer from poor
reproducibility, random orientation, low stability, and susceptibility
to environmental conditions, such as temperature, pH, and ionic
strength of the medium. In a study [86], positively charged PEI-FA
was conjugated, via electrostatic interaction, on negatively

maleimide coupling, epoxy-amine coupling, and isocyanate-amine
coupling methods. With the advent of multifunctional PEG, it is
possible to decorate DMSNs and conjugate targeting agents onto
the incorporated PEG polymer chain [127,128].
Furthermore, with the proper implementation of spatiotemporal targeting approaches, nanostructures can enhance the accumulation of the loaded drugs at the desired place, preserve drug
leakage, eliminate off-target effects and provide controlled drug
release [129,130]. Speciﬁc targeting of the nanoformulations towards the desired site of action and controlled cargo delivery is
conducted through active targeting, and by implementing stimuliresponsive approaches. Although the passive and active targeting
concepts are designed to accumulate the loaded therapeutic/diagnosis agents at the site of action and provide spatial targeting, the
stimuli-responsive systems provide temporal targeting in addition
to spatial targeting [109,131]. Notably, it is possible to apply
different spatiotemporal targeting strategies to DMSNs due to
tunable size and well-established conjugation chemistry.
Different surface functionalization strategies with speciﬁc
ligand/targeting agents for active targeting have been described
showing a signiﬁcant increase in the accumulation, retention, and
internalization of NPs into the targeted cells [132,133]. The active
targeting approach is complementary to the passive delivery
concept. The conjugated/attached ligand/targeting agents are
associated with speciﬁc receptors or molecules overexpressed in
diseased tissues, cells, or subcellular domains. Accordingly, the
10
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Fig. 5. Illustration of the different grafting methods used for PEGylation.

acid receptors (FRs) are highly overexpressed in different cancers
and have a high afﬁnity to its ligand, making folic acid (FA) a
promising targeting agent. Accordingly, a lot of attention has been
given to developing folate conjugated NPs as active targeting
agents. In a study, Wang et al. [70] used APTES to include NH2
functional groups on curcumin-loaded DMSNs and applied the
EDC/NHS coupling chemistry to conjugate FA. They reported that
DMSNs increased Cur-induced intracellular ROS generation and
MCF-7 apoptosis rate. In another study, Dai et al. [164] applied the
same approach, APTES surface modiﬁcation, and EDC/NHS coupling
chemistry, to conjugate FA on doxorubicin-loaded DMSNs
(DOX@DMSNs). The authors also used N, N-phenylene bis-(salicylideneimine)dicarboxylic acid (Salphdc) as both, a gatekeeper and
as a ﬂuorescence imaging probe. They reported that the synthesized DOX@DMSNs were internalized by HepG2 cells through the
FA receptor-mediated endocytosis process. Studies on a liver tumorbearing nude mouse model showed that DOX@HPSNSalphdcFA
administration induced better curative results than the control (PBS
and free DMSNs) and free DOX (Fig. 7 A, B, and C). Moreover, biodistribution studies (Fig. 7 D, E, and F) revealed that the
DOX@HPSNSalphdcFA effectively accumulated into tumor tissue
and the efﬁcacy of DOX@HPSNSalphdcFA for tumor targeting
was signiﬁcantly higher (p<0.01) than that of non-targeted NPs
(DOX@HPSNSalphdc).

charged TiO2-coated, Cur-loaded DMSNs. The PEI-FA served not only
as the surface modiﬁer but also as the gatekeeper agent preventing
curcumin release from the TiO2-coated DMSNs pores. The results
showed that the cytotoxic effects of FA conjugated NPs on HeLa cells,
folate receptor overexpressing cell, was signiﬁcantly higher than
that of A549 cells, folate receptor-negative cells.
On the other hand, the chemisorption beneﬁciates from the
chemical reactions between the DMSNs surface and the targeting
agents. In this scenario, the surface of DMSNs should possess
functional groups for the intended chemical reaction. DMSNs are
relatively easy to functionalize due to multiple silanol groups
(SieOH) on the surface. These silanol groups can be modiﬁed for
different conjugation methods. The induction of functional silanes
on the DMSNs through either co-condensation or afetr-synthetic
grafting is a practical approach for targeting agent conjugation
[161]. The co-condensation method generates the functional silanes
on the DMSN's surface and inside the pores of the DMSNs. At the
same time, after-synthetic grafting generates the functional groups
mainly on the surface. The conjugation of targeting agents on
DMSNs can be conducted utilizing some commercially available
crosslinking agents, such as maleimide-PEG-N-hydroxysuccinimide
(Mal-PEG-NHS) ester, m-maleimidobenzoyl-N-hydroxysuccinimide
ester (MBS), and N-(a-maleimidoacetoxy)succinimide ester (AMAS)
(Fig. 6) [127,162].
The induced functional groups can be utilized for further
conjugation of different targeting agents. For example, Cai et al.
[163] conjugated triphenylphosphine (TPP), a mitochondriatargeting ligand, to Pt-decorated DMSNs for photodynamic therapy (PDT) applications. They used 1-ethyl-3-(3-dimethyl aminopropyl) carbodiimide (EDC)/N-hydroxysuccinimide (NHS) coupling
chemistry to attach TPP on DMSNs. The authors reported that the
synthesized nanoplatform showed an enhanced PDT effect. Folic

4. Diagnostic applications
4.1. Imaging
The application of magnetic NPs and mesoporous silica nanoparticles has attained much attention since these NPs can provide
tunable innovative imaging properties that can be utilized in
11
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Fig. 6. Chemical structure of commonly used organosilanes.

functionalization of miscellaneous molecules like proteins, peptides, and enzymes [22,167,168]. The speciﬁc surface modiﬁcation
of the DMSNs can be applied in the ﬁelds of diagnosis or sensing of
particular molecules. DMSNs have been used in immobilizing enzymes to improve the signal in detection tests (Fig. 8A and B). The
large surface area and large porosity of the DMSNs enable them to
encapsulate high levels of biomolecules. Moreover, the large
porosity of the DMSNs provides a large contact area between the
substrate and the encapsulated biomolecule. Based on this, Lei et al.
[22] loaded horseradish peroxidase (HRP) inside the DMSNs to
increase insulin detection. The authors used DMSNs with a pore
size of 14.5 nm and pore volume of 1.39 cm3g 1 (Fig. 8B) and
demonstrated that the obtained insulin kit was 2000 times more
sensitive than the commercial insulin ELISA kit [22]. In another
example, DMSNs containing HRP were functionalized with poly(amino acid) multilayers (PAMs), which enhanced the ELISA's
sensitivity to about 104 times higher than the conventional ELISA
tests (Fig. 8C) [168]. Liu J. et al. constructed efﬁcient chlorpyrifos (a
widespread chemical compound generally used to extinguish insects) aptameric biosensor using dendritic ﬁbrous nano-silica
(DFNS) particles functionalized with an amino group (NH2-DFNS)
with enhanced sensitivity [166].
Chondroitin sulfate (CS), a natural glycosaminoglycan structure,
provides suitable sites for the absorption the speciﬁc molecules
[167]. CS conjugated with amino-terminated dendritic mesoporous
silica nanoparticles (A-DMSNs) can isolate or increase the

different diagnostic and therapeutic applications [106,165]. Floodndez-Rojas [165] synthesized magnetic wrinkled
Garibay and Me
mesoporous silica nanoparticles (MWMSNs) with two separate
methods. In the ﬁrst approach, the magnetic NPs were included
during the preparation of the WMSNs, and in the second procedure,
magnetic NPs and WMSNs were mixed using ultrasound waves.
The ﬁrst method resulted in core-shell magnetic nanoparticles,
while the second resulted in WMSNs containing magnetic NPs on
the surface. Both particles had excellent magnetic properties and
could effortlessly be separated by an external magnetic ﬁeld from
aqueous suspension, and showed great potential in applications
like imaging contrast agents and targeted drug delivery [165]. Li
et al. [107] reported the combination of FeOCl as a contrast agent
for T2-weighted MR imaging with dendritic mesoporous organosilicon. The nanoparticles were used to improve the restriction of
the Fenton reaction in chemodynamic cancer therapy for imaging
[166]. Up-conversion dendritic mesoporous silica NPs encapsulating copper peroxide have also been prepared and used in cancer
treatment and imaging applications [108].
4.2. Diagnostic assays and adsorption applications
The tunable characteristics of DMSNs make them great candidates for various biological applications. DMSNs have a large surface area with adjustable pore diameter and a large volume of
radial porous channels that provide many sites for the
12
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Fig. 7. (A) After treatment, photo images of tumor tissues with PBS (control), HPSNs, DOX, DOX@HPSN, and DOX@HPSNSalphdcFA for 0, 7, and 20 days, respectively. (B) Final
weights of tumor tissues treated with drug/nanoparticles for 20 days. (C) Relative tumor volumes of nude mice after different treatments. (D) Whole-body real-time ﬂuorescence
imaging of DOX@HPSNSalphdc (I) and DOX@HPSNSalphdcFA (II) for 1, 3, 6, 12, 16, 24, and 48 h, respectively. The dash cycles represent the tumor locations. Scale bars: 3 cm. (E)
Histogram of the ﬂuorescence intensity of tumors after injection of DOX@HPSNSalphdc and DOX@HPSNSalphdcFA for 1, 3, 6, 12, 16, 24, and 48 h, respectively. (F) Images of
main organs (spleen, tumor, kidney, liver, lung, and heart) after injection of DOX@HPSNSalphdcFA for 16 h. The error bars indicate that the mean is ±SD (n ¼ 4). (**) It is
reproduced from Ref. [164] with permission from the American Chemical Society.
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membrane of the cancer stem cells [99]. In addition to chemical
drugs, DMSNs have also been used to design nanozymes by
encapsulating small metal ions within their porous structure to
induce cancer cell death and regression of solid tumors [16]. In
another work, the authors developed cyclometallated gold
complex-containing DMSNs functionalized with folic acid as targeting ligand. The work demonstrated that DMSNs were taken up
by MCF-7 cells via receptor-mediated endocytosis. Moreover, the
release of the cyclometalleted Au complex was reported to be pHdependent [66]. In another example, Taleghani et al. loaded the
iron-chelating agent Deferasirox on DMSNs to reduce high concentrations of iron in cancer cells. Li et al. prepared the nanocomposite
FeOCl@H-DMOS-AA/PEG
based
on
hollow
dendritimesoporousus organosilicon (H-DMOS) loaded with iron
oxychloride (FeOCl), ascorbic acid (AA), and coated with poly
(ethylene glycol) (PEG) [107] and found that the nanocomposite
produced high levels of toxic hydroxyl radicals even at pH 7. The
system was very effective in eliminating the tumor in a mice model.
Another interesting approach to induce cytotoxicity in the TME
using DMSNs involves the delivery of enzymes for depleting lactate
in tumors. Tumor cells uptake glucose via aerobic glycolysis and
produce lactate in large volumes. The produced lactate regulates
angiogenesis, tumor invasion, and metastasis due to acidiﬁcation of
the TME. Lactate oxidase (LOX) is an 80 kD enzyme specialized in
oxidizing lactate to pyruvate and hydrogen peroxide [176]. Due to
the high concentration of lactate in tumors (10e40 mM) [177], high
amounts of LOX are needed for efﬁcient lactate depletion. Depletion
of LOX has two consequences in tumor biology (1) antiangiogenesis and anti-metastasis effects following the downregulation of VEGF and (2) generation of cytotoxic H2O2 and raised
hypoxia. Besides hypoxia has been used to activate hypoxiaresponsive prodrugs such as AQ4N (or banoxantrone) [178]. Due
to the high toxicity of high LOX doses, Tang et al. developed innovative openwork@dendritic mesoporous silica NPs (ODMSN) for
LOX and AQ4N delivery to the TME. The synthesized ODMSNs
showed a particle size of 176 nm. These NPs have a large pore
diameter (~27 nm), high surface area (~9 16 m2 g1), and pore
volume (~4.02 cm3 g1), making ODMSN an excellent carrier for
LOX with a high loading capacity (~731.8 ± 15 mg mg1) [178]. The
DMSNs developed delivered LOX to the tumor and were able to
catalyze lactate oxidation to pyruvate and H2O2 in mice in vivo. The
nanoparticles decreased the lactate concentration by more than
95%, generating cytotoxic H2O2, elevating hypoxia, and activating
the co-delivered prodrug AQ4N (Fig. 9A, i). This combinatorial
treatment of DMSN þ LOX þ AQ4N achieved a 100% survival rate in
mice. The combination of DMSN þ LOX þ AQ4N enhanced tumor
hypoxia (Fig. 9A, ii) and a reduction in angiogenesis and VEGF
expression (Fig. 9Aeiii). These effects remained for 72 h, which
delayed the tumor growth from 6 to 9 days, while the direct
administration of LOX resulted in a high death rate of ince [179].
Fan et al. reported the use of the combination of NO and
cisplatin, and wrinkled mesoporous silica NP (AMS) to eliminate
NSCLC cells. Nitric oxide (NO) is one of the well-known physiological messenger agents which plays an important role in angiogenesis, immune responses, apoptosis, and cardiovascular
homeostasis [68,181,182]. However, a drawback of NO molecules is
their poor stability and very restricted half-life [183e185]. In cancer
treatment, NO efﬁciently kills cancer cells through the oxidation or
nitrosation of mitochondria and DNA. Interestingly, NO can sensitize cancer cells to cisplatin. The authors demonstrated that
adsorbed cisplatin on amine-functionalized N-diazeniumdiolate
(as NO donors) AMS induced the eradication of NSCLC cell lines
[186].
Photodynamic therapy (PDT) combines light energy and a
photosensitizer to generate reactive oxygen species (ROS) to kill

concentration of biological compounds such as proteins since CS
composition is similar to low-density lipoprotein receptor (LDLR).
Cao et al. conjugated A-DMSNs with CS to absorb low-density lipoproteins (LDL) (Fig. 8D). The proposed method showed excellent
efﬁciency in capturing the LDL from sample matrices, revealing that
can separate speciﬁc proteins among complex biological samples
[167].
In another study, mesoporous structured silica nanoﬁbrous
membranes (MPSNMs) were produced to absorb tetracyclines (TCs)
from wastewater and sewage. MPSNMs provided high surface area,
high porosity with large pore volume ﬁbers with ﬂexible mechanical
properties which could be bent easily without being fractured. The
authors demonstrated that two main mechanisms, i.e., hydrogen
bonding and electrical attraction interactions, participated in TCs
absorption, which had a synergic effect on the capacity of MPSNMs
to harvest the TCs from aqueous suspensions [169].
Jiahu et al. [170] also produced dendritic ﬁbrous nano-silica
(DFNS) nanoparticles anchored with Nd2Sn2O7 as an active photocatalyst. The proposed coated NPs demonstrated a great capacity
to absorb metronidazole from the aqueous solutions [170].
5. Therapeutic applications of DMSNs
The use of DMSNs for various therapeutic applications such as
chemo-, photodynamic- (PDT), photothermal- (PTT), sonodynamic, chemodynamic- (CDT), and immuno-therapy as well as for the
treatment of different infectious or inﬂammatory diseases and
tissue regeneration have been reported. Using DMSNs, it is possible
to encapsulate drugs, and biomolecules, and also to engineer drug
delivery vehicles that allow a spatiotemporal release of therapeutic
cargo while minimizing undesirable toxic effects compared with
conventional treatments.
5.1. Utilizing engineered DMSNs for drug delivery in cancer
Several strategies, including surgery, radiotherapy, and chemotherapy, have been employed in clinics for cancer therapy [171], and
are widely used. Moreover, several drug-loaded nanoparticles have
been reported to target the tumor tissue and generate a therapeutic
response. Besides, as we mentioned above, DMSNs are potential
platforms with high loading capacity and can be easily designed to
respond to external or internal speciﬁc stimuli. In the case of cancer,
the tumor microenvironment (TME) provides several stimuli that
can be used to trigger drug delivery. Moreover, the modulation of
TME using nanotechnology has gained attention in recent years
[172e174], and it has been found that DMSNs could help cancer
therapy by regulating various speciﬁc factors in the TME [175].
Hallmarks of the tumor microenvironment (TME) include hypoxia,
high interstitial ﬂuid pressure, increased glutathione (GSH)
expression, increased concentration of H2O2, increased lactate
production, expression of vascular endothelial growth factor VEGF,
expression of speciﬁc receptors like folic acid and CD133, and an
increased expression of GLUT (glucose transporter). Typically,
DMSNs are loaded with one or a combination of payloads, which
can apply via injection either intravenously or directly to the tumor
location, with the subsequent DMSNs internalization in cancer cells
via endocytosis where the drug is released.
A pH change can trigger cargo release in pH-responsive DMSNs,
and several examples using this mechanism have been reported for
cancer therapy. Dextran-coated DMSNs loaded with DOX were
covalently bonded to a CD133 aptamer to deliver DOX to HT-29
tumor cells. With a pore size in the range of 2e25 nm, the modiﬁed DMSN was internalized rapidly, showing an accelerated drug
release at pH 5.4. The authors demonstrated that the nanoparticles
are helpful to target the overexpressed CD133 receptors on the
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Fig. 8. Application of DMSNs in sensing the biological molecules. (A) Conventional ELISA testing method. (B) DMSNs encapsulated HRP was used in a similar ELISA, which resulted
in higher sensitivity of the Insulin detection [22]. (C) DMSNs loaded HRP modiﬁed with poly(amino acid) multilayers were applied to increase the sensitivity and stability of the
ELISA system [168]. (D) The amino-terminated dendritic mesoporous silica nanoparticles (A-DMSNs) functionalized with chondroitin sulfate (CS) were structured to capture the LDL
[167].

solid tumors using nanoparticles. Its efﬁciency is tied to the accumulation of targeted therapeutic nanoparticles, the intensity of the
light stimulus, and the light-heat conversion efﬁciency. The accumulation of nanoparticles in the target site is key to the effectiveness of PTT. Liu et al. engineered manganese-based DMSNs
(DMMnSiO3) loaded with indocyanine green (ICG) and glucose
oxidase (GOD). The authors demonstrated that the nanoparticles
quickly disintegrated in tumor cells due to the presence of glutathione (GSH) and mildly acidic conditions, effectively releasing
Mn2þ, GOD, and ICG. Mn2þ was released from the nanocomposite
in a uniform and sustainable manner and acted as a catalyst in
oxygen generation from intratumoral hydrogen peroxide. Moreover, GOD was used to consume glucose and generate H2O2 and ICG
produces PTT upon irradiation at 808 nm. A similar approach was
followed by Huang et al. [180] using DMSN loaded with Catalase
and ICG, under multimodal ultrasound/photoacoustic imageguided tumor photodynamic therapy. Catalase enzyme in the
nanostructure helps in the decomposition of H2O2 to produce O2 for
the tumor, which is crucial for enhancing the PTT therapeutic efﬁciency (producing ROS for cancer cell killing) that was effective by
the presence of ICG and irradiation at 808 nm [180]. (Fig. 9C). In
another study, the targeting efﬁciency of DMSNs was increased by
coating their surface with cell membranes. These biomimetically
camouﬂaged NPs demonstrate superior properties in blocking the
premature release of drugs loaded into NPs and improving the
binding to cancer cells due to self-identiﬁcation, leading to longer
blood circulation times [191]. In a similar study, red blood cell
membrane camouﬂaged DMSNs imparted additional stability to
the DMSN NPs. The DMSNs were then co-loaded with copper sulﬁde to improve photothermal and radio-sensitization properties for
anti-tumor efﬁcacy [192]. In another study, DMSNs with leukocyte/
platelet hybrid membrane co-loaded with doxorubicin and a NIR
ﬂuorescent dye showed an improved targeted efﬁciency towards
triple-negative breast cancer. The average pore diameter of 9.0 nm
led to a large drug loading capacity (T. Znag et al., 2021). Li et al.
embedded oil-soluble Ag2S QD crystals, as NIR responsive nanoparticles, in 60 nm DMSN with doxorubicin-loaded in the DMSN
pores [193].
Overall, DMSNs with a good dispersity and spherical, uniformlydendritic morphology have efﬁciently been used in a synergistic
approach by combining PTT and PDT modality to enable a catalystdriven cascade mechanism [106]. The properties of DMSNs can be
further enhanced by integrating a functional host within the nano
platform to provide distinct properties. For example, graphene
nanosheets used as a host within the DMSNs improved biocompatibility, biodegradability, surface area, and drug loading capacity.
Upon conjugation of curcumin-loaded, graphene oxide integrated

cells [187]. More than one type of ROS can work in synergy, and for
instance *OH is used along with 1O2 to damage bioorganic molecules, including DNA, lipids, and proteins. For PDT, lasers and noncoherent light sources have been used [188]. This process can be
employed in combination with a mechanism that feeds O2 to the
tumor, for instance, using catalysts that can break down compounds to generate O2. For example, multifunctional DMSNs have
been developed using silica doped with fullerene C60 as photosensitizers and ﬂuorescent agents for imaging, combined with the
loading of the hydrophobic C18 and anti-pAkt mAb as therapeutic
cargo. Besides, the fullerene in the silica core was used to generate
single oxygen (1O2) [57]. In a similar study, the combination of an
antibody against AKT serine/threonine kinase 1 (mAb anti-pAkt),
related to cell survival, and PDT signiﬁcantly reduced Bcl-2 protein levels compared to each treatment alone. Furthermore, the
growing up of DMNSs on the C60 core gives two important features
to the synthesized composites, including ﬂuorescent intracellular
tracking and signiﬁcant inhibition of cell viability [57]. In another
study, Ce6 photosensitizer-loaded Pt-decorated DMSNs functionalized by a mitochondrion targeting ligand were successfully
developed for improving PDT therapeutic effect in A549 lung cancer cells. As the presence of O2 is an essential pre-requisite for
enhancing the PDT efﬁcacy, in this work, targeting mitochondria by
nanoparticles that had catalytic activity for producing H2O2 was
used to tackle the tumor hypoxic microenvironment [57].
A sustainable ROS generator was developed by Liu et al. for antitumor therapy. The internal pores of hyaluronic acid (HA)-DMSNs
(pore size 20 nm) were loaded with Mn3O4eCe6 (MC) particles and
tested in vitro on the murine breast cancer 4T1 cell line. The
rationale behind the encapsulation was the high concentration of
HAase in the tumor. The HA layer was digested by the enzyme
HAase causing a release of MC particles in the tumor vicinity. The
tumor cells then internalized the MCs and degraded them by GSH
to release Mn2þ ions and the photoinitiator, Ce6. Ultimately, the
irradiation of Ce6 produced 1O2 species. Moreover, the Mn2þ ions
converted H2O2 to *OH [189]. Besides, multi-functional nanoplatforms using DMSNs and up-conversion NPs for MRI and CT scanguided PDT was developed by Liu et al. The authors synthesized
DMSNs with a mesoporous silica coating to increase the loading
capacity of copper peroxide nanodots, Ce6, and polyethylene glycol
(PEG) into the silica pores. The primary function of DMSNs was to
enhance NO generation and Cu2þ release in TME, while lanthanide
ions in UPCN imparted luminescence for imaging [108]. (See
Fig. 9B).
Photothermal therapy (PTT) induces cell apoptosis by increasing
local heat generation by exposing heat-generating materials to
near-infrared radiation (NIR) [190]. PTT is a localized treatment for
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Fig. 9. A) (i) changes in the concentration of Lactate in the 4T1 tumors model after 48 h of DMSN injection. (ii) hypoxia level under different treatments, (iii) VEGF level based on
stained area for tumor sections [178]. B) (i) the UMNOCC-PEG synthesis illustration, (ii) the therapeutic mechanism introduced for UMNOCC-PEG to improve PDT induced by gas
therapy, Cu2þ-initiated chemodynamic therapy, and NIR [108]. C) The synthesis process of FeOCl@H-DMOS-AA/PEG [107]. D) the (i) biodegradation process of DMMnSiO3 NPs
loaded with ICG and GOD, (ii) the concentrations of released Mn2þ in TME at different times, (iii) dissolved oxygen concentration in TME [180].

loading capacity to deliver multi-therapeutic agents for TME
modulation in drug-based and enzyme-based therapy.
Sonodynamic therapy (SDT) encompasses non-thermal therapeutic ultrasound applications. The mechanism behind the working of SDT is not yet fully understood. However, the ultrasonic
cavitation effect is a possible contributing factor to the efﬁcacy of

DMSNs with folate; a PTT platform was established to release curcumin to induce cell apoptosis. Similarly, gold NPs were immobilized in the DMSNs as PTT agents [194]. All these examples
demonstrated the potential of DMSNs, due to the controllable pore
sizes, wide speciﬁc surface area, unique structures, biodegradability, good biocompatibility compared to typical NPs, and high
16
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nanomaterial-based immunotherapy has shown promising to
potentiate the efﬁcacy of cancer immunotherapy and reduce side
effects. Different NPs can be used to deliver cancer antigens and
therapeutic drugs to cancer cells. In addition to the medicinal
cocktail, NPs are often modiﬁed to carry adjuvants that enhance
treatment efﬁcacy. Xing et al. synthesized dendritic porous silica
nanoparticles (DPSNs) modiﬁed with aminopropyl groups and
loaded with bovine serum albumin (BSA). The NPs achieved an
efﬁcient loading of BSA protein and provided a versatile method of
synthesizing DPSNs with tunable asymmetric features [202]. Shi
et al. reported a light-traceable, intracellular microenvironmentresponsive drug delivery system that was synthesized using a
combination of DMSNs, gold NPs, and autoﬂuorescent nanogels.
This carrier was loaded with sulfhydryl-containing drug (Captopril). The drug delivery system achieved low cytotoxicity, efﬁcient
transport ability, and microenvironment-responsive drug release
[203]. However, considering the size of most adjuvants and immunotherapeutics (such as proteins and cytokines), the mesoporous structure and the size of NPs is a crucial factor. This sizerelated constraint paves the way for DMSNs due to their relatively small particle size and large pore size. Among the different
strategies, cancer vaccination is the most widely applied for cancer
immunotherapy, and DMSNs have attracted signiﬁcant attention
for vaccine development due to their properties. NPs can be applied
as carriers for vaccines and adjuvants to boost immune response
[204e206]. Immunomodulatory agents or immunogens are the
main parts of an NPs-based vaccine, containing antigens, DNA
vaccines, and siRNA [207,208]. These substances can be encapsulated (within NPs lumen, pores, or cavities), conjugated (via covalent linkages), or adsorbed (on the surface of the NPs) [209].
Moreover, immunostimulatory and targeting ligands, such as tissue
and immune-speciﬁc ligands, and pathogen-associated molecular
patterns (PAMPs) can be incorporated into the NPs-based vaccine to
target speciﬁc cell tissues and elicit inﬂammatory responses.
[210e212]. It is documented that the intended vaccine needs
drainage to lymph nodes, internalization by dendritic cells (DC),
maturating DCs, and proceeding and presenting MHC I-antigen
complexes to CD8þ T cells (Scheme 2) [213,214]. In this cascade, the
critical step is the internalization of antigen-loaded NPs into DCs;
otherwise, the drained NPs leave the lymph node through the
subcapsular sinus and the efferent lymph vessel [213,215]. Moreover, it was shown that NPs with a size range of 10e100 nm could
pass through the lymphatic endothelial cell gaps and drain into the
lymph nodes [216e218] (see Scheme 3).
Biocompatibility, tunable size, easy surface functionalization,
ultrahigh speciﬁc surface area, and adjustable pore size and
chemistry make DMSNs suitable for vaccine delivery applications.
Moreover, negative surface charge and hydrophilic surface due to
silanol groups (SieOH) make DMSNs potential lymph nodetargeted carriers [71,219]. Several studies utilized DMSNs for vaccine development. Hong et al. [213] synthesized 80-nm DMSNs
with different pore sizes loaded with ovalbumin (OVA) antigen to
assess the effect of pore size on the mediated-immune responses.
The authors labeled OVA with Cy5 (cyanine5) dye to track the
derange of DMSNs from the administration site to lymph nodes
in vivo and their internalization efﬁciency in DC2.4 cells. They
observed that subcutaneously injected Cy5-OVA@DMSNs
accumulated into popliteal lymph nodes 10 h after injection
(Fig. 10).
In another study, Jambhrunkar et al. [220] synthesized an
immunoadjuvant and co-delivery platform based on benzenebridged mesoporous organosilica NPs for delivery of both antigens (OVA) and toll-like receptor-9 agonists (cytosine-phosphodiester-guanine oligodeoxynucleotide(CpG)). The authors reported
that the incorporation of the bridged organosilica framework

SDT [195,196]. As a result of this cavitation effect, sonoporation
occurs. This causes transient micropores that ease the vascular
permeability of drugs and improve their transport across the cell
membrane [196]. The SDT can also induce cancer cell apoptosis via
the regulation of gene expression and angiogenesis. Sonosensitizers in a drug-delivery platform used in SDT get excited upon
ultrasound irradiation and release energy upon returning to the
ground state. The molecular O2 absorbs this released energy to
generate ROS. Different sonosensitizers like TiO2 offer good thermal
and photostability along with excellent biocompatibility. Although
SDT cannot be used as a stand-alone therapy to eliminate tumor
cells, it can increase cytotoxicity by enhancing the uptake and
release of drugs. For example, the therapeutic efﬁciency of
polyethyleneimine-folic acid-coated DMSNs loaded with curcumin
used in SDT showed encouraging results as an anticancer platform.
Folic acid was used as a targeting ligand and was linked to the
DMSNs via polyethyleneimine. Curcumin was loaded onto the
DMSNs as an anticancer drug. Curcumin was released in a
controlled manner, and its release rate depended on the ultrasound
irradiation time. When the DMSNs were tested on the HeLa and
A549 cells, excellent anticancer activity was observed [86]. In
another study, Zuo et al. designed DMSNs containing ultrasmall
Cu2-XS NPs and Rose Bengal (sonosensitizer). These DMSNs were
used to target oral squamous cell carcinoma (OSCC). When irradiated with both NIR laser and ultrasound, OSCC cell death was
induced. Furthermore, the intravenous administration of these
DMSNs into mice showed satisfactory biocompatibility and biodistribution at the tumor sites [197].
Chemodynamic therapy (CDT) produces *OH radicals from H2O2
via Fenton and Fenton-like reactions [198]. The CDT leverages the
overproduction of H2O2 to produce free radicals that induce cytotoxicity in cancer cells. The NPs utilized in CDT usually incorporate
enzymes or inorganic particles that catalyze the reduction of H2O2.
A continuous supply of H2O2 is necessary for a successful CDT. For
this purpose, DMSNs have been used as large-pore supports to
encapsulate bulky enzymes and nanoparticles. A large-pore DMSN
support incorporating Fe3O4 NPs set up sequential catalytic reactions to liberate *OH radicals. The large pore size (40 nm) of the
DMSN platform also contained glucose oxidase enzyme to maintain
a supply of H2O2 [199]. Besides, Li et al. recently developed a hollow
DMSN system, conﬁning FeOCl NPs within the silica structure. In
this study, ascorbic acid was used as a prodrug for the generation of
H2O2. It was shown that ascorbic acid in the extracellular environment in the presence of serum could produce ascorbate radicals,
and subsequently, these radicals produce H2O2 which ﬁnally promotes cancer cell death. Further, this system also showed effective
metastasis inhibition and enabled T2-weighted MRI capability
[107]. Li et al. designed a nanozyme formulation by co-loading CaO2
and Fe3O4 NPs within a pH-sensitive DMSN construct. Following
intravenous injection in mice, DMSNs released the NPs within the
weakly acidic media in TME. The released CaO2 reacted with the Hþ
ions to produce H2O2 that then underwent a Fenton reaction with
Fe3O4 to produce toxic *OH radicals. An efﬁcient synergistic
mechanism inducing ferroptosis and immunomodulation occurs
[18]. Like PDT, CDT can also be combined with other therapies such
as PDT and PTT for increased treatment efﬁcacy [200]. Dong et al.
coated uniformly sized down conversion NPs with DMSNs and then
loaded them with ultrasmall oxygen-deﬁcient molybdenum oxide
NPs. In vitro tests showed that HeLa cells efﬁciently internalized the
DMSNs, resulting in reduced survival of the cells. Moreover, the
nanoparticles were used for PTT and CDT therapy in an in vivo
model [201].
Immunotherapy for cancer treatment has been raised as an
alternative strategy to conventional treatments by stimulating the
immune system for cancer cell killing. Besides, in recent years,
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Scheme 2. Schematic representation of the adaptive immune response induced by antigen-loaded lymph nodeetargeting NPs.

Scheme 3. (a) A schematic illustration of the preparation and drug loading of SL-IDMSN. (b) Intracellular drug delivery by microenvironment sensitive SL-IDMSN [69].
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cannot be utilized systemically due to its highly toxic effects [236].
It was shown that activation of dendritic cells (DCs) by TNF-a
causes immune system-dependent antitumor effects. However,
high amounts of this drug (more than 1 mg) are needed to achieve
the desired antitumor activity. The administration of this dosage
systemically is impossible due to cytotoxic effects, and only local
use of this cytokine in melanomas, sarcomas, and unresectable
tumis are approved [237]. DMSNs, have been used for encapsulation and shielding of a highly toxic TNF-a homotrimer agonist
(Beromun) in combination with a pH-sensitive hyperbranched
polyethyleneimine (PEI)-polyethyleneglycol (PEG) copolymer [53].
In another example, extra-large pore mesoporous silica NP
(~20e30 nm) has been developed with high efﬁciency for IL-4
delivery [238].
Following chemoimmunotherapy, a lipid-coated biodegradable
hollow mesoporous silica nanoparticle containing two chemotherapy drugs (all-trans retinoic acid (ATRA) and doxorubicin
(DOX)) and the immune system regulator interleukin-2 (IL-2) was
developed for stimulating tumor immunity (Fig. 12A). The biodegradable and hollow mesoporous silica nanoparticles (BHMNS)
depicted high encapsulation capacity and excellent stability, with
low systemic toxicity. The sustained drug release behavior of
BHMNSs changed the cold immunity atmosphere of TME to a hot
environment via stimulation of T lymphocytes and natural killer
cells [239]. The remodeling of the TME immune system is changed
by the up-regulation of IFN-g and IL-12 and the down-regulation of
IL-10 and TGF-b [56]. Furthermore, nanozyme Pt NPs were deposited on the surface of the channels of DMSNs to catalyze the
intracellular H2O2 conversion to oxygen. Based on the results,
DMSNs could: i) carry a high amount of drugs due to their high
capacity, ii) enhance the catalytic activity and oxygen generation
(by decomposing the hydrogen peroxide inside the cell), iii) increase the death rate of cancer cells compared to the direct use of
drugs (Fig. 12B) [56,163,240].
DMSNs also demonstrated their potential to stimulate T cells
and TAM (tumor-associated macrophage) to promote tumor suppression. For instance, Chen and his colleagues synthesized DMSNs
loaded with iron oxide for cytotoxic T cell activation and macrophage polarization (Fig. 12C, i) [240]. CD80þ and CD86þ B cells, as
M1 markers, experienced higher activation and approximately 3e4
times upregulation to show antitumor effects. Due to iron oxide,
this activation was higher in DMSNs-based treatments than in the
current treatments (Fig. 12C, ii). The weight of the tumors was
measured after implantation (injections of vaccine for female C57/
BL6 mice), and the results showed that employing DMSNs caused a
signiﬁcant reduction in the weight of tumors (Fig. 12C, iii). The
principal reason was ascribed to the high loading potential of the
DMSNs.
Combinatorial cancer therapy can also be envisioned using
DMSNs involving PTT/starvation therapy/immunotherapy. In a
study by Li et al., the DMSN platform was co-loaded with Au NPs
and Imiquimod (R837), an immunostimulator. DMSNs were coated
with a pH-sensitive cell membrane to facilitate the loading of R837.
In vitro, cellular uptake results showed that DMSNs were efﬁciently
taken up by the 4T1 cells. Furthermore, in vivo results on mice
showed a synergistic effect of PTT/starvation therapy/immunotherapy on the tumor via tumor ablation. The study demonstrated
that the use of R837 along with Au NPs loaded on DMSNs generated
a vaccine-like function by inducing a long-term memory effect for
inhibiting tumors [17].

showed a signiﬁcant effect on the physicochemical properties of
NPs. The results indicated that the incorporation of benzene bridge
groups resulted in high pore volumes and large pores, with subsequent effective OVA and CpG delivery to DCs. The animal studies
showed signiﬁcant tumor inhibition with 100% tumor-free mice in
25 days.
Cha et al. [219] synthesized a prophylactic cancer vaccine based
on extra-large pore DMSNs loaded with OVA and CpG to stimulate
antigen-speciﬁc cytotoxic T lymphocytes (CTLs). The results
showed promoted antigen presentation and stimulation of DCs and
enhanced pro-inﬂammatory cytokines secretion. Animal studies
revealed draining lymph nodes targeting the DMSNs, stimulation of
CTLs, and signiﬁcant tumor growth suppression. Another study
synthesized extra-large pore DMSNs coated with PEI polymer to
endow adjuvant immune properties and modiﬁed the NPs surface
charge to improve loading and slow release of OVA [221]. The results showed promoted activation of the DCs, the CTLs, tumor
growth suppression, and enhanced survival rate. Abbaraju et al.
synthesized asymmetric DMSNs with tunable headtail structures
for vaccination and immunotherapy. The authors reported that the
structure of the head is adjustable (porous or solid), whereas tail
features (tail coverage on head and tail length) are tunable by
varying the TEOS volume and reaction condition (Fig. 11). The results showed that the synthesized asymmetric DMSNs exhibited
excellent biocompatibility and hemocompatibility. Moreover, uptake and maturation induction of immune cells (macrophage and
DCs) through the synthesized asymmetric DMSNs was higher than
€ber spheres NPs [222].
when using Sto
In addition, previous research has shown that reactive oxygen
species (ROS) could serve as an essential stimulator of immune
responses [223,224]. These molecules can prompt the stimulation
of dendritic cells (DCs) [225,226] by an increase of CD86 and CD80
for enhancing antigen presentation [227]. In this regard, organosilica dendritic NPs with tetra-sulﬁde bond structure and functionalized with polyethyleneimine (PEI), are able to GSH-depletion,
ROS generation capability, and ability to co-deliver ovalbumin/
cytosine-phosphorothioate-guanine (CpG) to immune systems
were developed. Neutralizing intracellular GSH levels with tetrasulﬁde bonds caused increased ROS levels. Also, after being delivered into APCs the is a release of antigen and agonist triggered by
the disintegration of nanocomposites in response to cytosolic high
GSH concentration (2e10 mM). Afterward, T cell (CD8þ) mediated
tumor cell death occurred [71].
As mentioned earlier, crosstalk between cancer cells and other
cells located in the TME causes the release of speciﬁc biochemical
agents that strongly paralyzes the tumor resident immune cells in
TME [228,229]. For example, immature myeloid-derived suppressor cells (MDSCs) release suppressive factors to inactivate T cells in
response to the abovementioned biochemical agents in the TME
[230,231]. So, a new therapeutic paradigm and novel strategies are
necessary to activate TME resident immune cells or inﬁltrate
external immune cells into the TME [232]. In recent years, the
combination of chemotherapeutic agents accompanied by immunostimulatory agents has been introduced as a new strategy. In this
aspect, the exposure to a certain cytokine mixture can act as an
activating signal, for the maturation of DCs from monocytes [219].
DCs, after the uptake of extracellular antigens, become mature and
present major histocompatibility complex (MHC) type I their its
surface. The antigen processing DCs travel to lymph nodes and
stimulate the cytotoxic T lymphocytes (CTLs) through the MHC-I
complex and T-cell receptors [233,234]. Given that most immunostimulatory agents are macromolecules, the usage of DMNSs for
this purpose is a great opportunity while undesired side effects are
minimized. For example, TNF-a is an essential protein mediator in
cell survival, inﬂammation, apoptosis, and immunity [235] that

5.2. Gene therapy
Human gene therapy (GT) is rapidly gaining popularity due to
the development of novel gene carriers [241e244]. The advent of
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Fig. 10. The DMSNs derange from the administration site to lymph nodes in vivo imaging using an IVIS Spectrum system. p, photon. Reproduced with permission from [213].

provides a clear rationale for utilizing large-pore DMSNs for loading
genetic content. In a traceable gene delivery platform, DMSNs were
loaded with 30 mg plasmid DNA (pDNA) per mg of NPs. To avoid
electrostatic interactions and increase gene transfection efﬁciency,
the DMSN surface was functionalized with an acetaldehyde-

adenoviral vectors and lentiviral vectors enables GTs for acquired
and inherited genetic disorders. Currently, silica NPs-based GT
suffers from low efﬁciency of passive-diffusion release of DNA and
RNA due to strong electrostatic interactions between negatively
charged genes and positively charged NP surface. This problem

Fig. 11. TEM images of DMSNs prepared at varied TEOS volume V. (A and D) V ¼ 0.41 mL, (B and E) 1.25 mL, and (C and F) 3.75 mL. Reproduced from Ref. [222] with permission from
the American Chemical Society.
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Fig. 12. A) BHMSNs could release all three factors to kill cancer cells and regulate TME [56]. B) synthesis of DMSNs-based NPs and how they enhance PDT. C) (i) T cell activation and
polarization of macrophages occur by DMSNs (IO-LPMONs) as signiﬁcant antitumor immunotherapy [163]. (ii) Expression of CD86 and CD80 in the co-culture systems under
different treatments, (iii) Tumor volume during in-vivo study under different treatments [240].

modiﬁed-cysteine [73]. DMSNs with ﬁbrous structures and large
pores (KCC-1) are better suited for transporting DNA and genes due
to their effective adsorption property. Genes can be readily adsorbed onto the internal or external surface area of KCC-1 [20].
Simultaneous delivery of a drug and genetic materials is another
exciting and promising approach for combating diseases. To
address this, an imidazole modiﬁed DMSN (SL-IDMSN) was used as
a pH-responsive system for delivery of DOX and Survivin shRNA
plasmid (iSur-pDNA) [69]. In this system, imidazole rings get a
positive charge at acidic pH, which helps to more intense electrostatic condensation of plasmids and protects them from blood
endo/exo nucleases. In addition, in the environment of endo/lysosomes, the Schiff-base linker with imidazole is hydrolyzed, allowing plasmid release. Moreover, the proton sponge effect due to
imidazole groups allowed endosomal scape and spread of the
plasmid into the cytosol.
Polyethyleneimine (PEI) functionalized DMSNs have been also
used to co-deliver topotecan and pEGFP-N1 plasmid effectively into
HeLa cells [245]. Similar to DNA delivery, mRNA was packaged
within a surface-modiﬁed DMSN to improve endosomal escape
[246]. In another study, DMSNs were integrated with other NPs to
improve the co-delivery efﬁciency of small molecules and genetic
materials. For instance, cyclodextrin-modiﬁed PAMAM (b-CD
PAMAM) dendrimers were used to load various therapeutic agents,
including hydrophobic and hydrophilic anticancer small molecule
and siRNAs genetic materials [247,248]. Also, DMSN and b-

cyclodextrin-modiﬁed PAMAM (3.0G) dendrimers were used to
deliver both the anticancer small molecule nitrophenyl benzyl
carbonate [249,250] and Bcl-2 siRNAs with high efﬁciency [73].
5.3. Engineered DMSNs in tissue applications
Recently, DMSNs have attracted interest in tissue engineering
(TE) applications due to their easy functionalization, high speciﬁc
surface area, good biocompatibility, tunable pores, and abundant
surface chemistry [251e253]. According to our survey, although
DMSNs have attracted tissue engineers' attention, only a few
studies have been published in the literature, but an increasing
trend was observed. Different roles of DMSNs in TE primarily focus
on the delivery of bioactive factors, bioactivity, stem cell labeling,
and the impact of MSNs on mechanical and physicochemical
properties of scaffolds (Nicely reviewed by Chen [254]).
5.3.1. Bone tissue engineering
Previous studies revealed that the release of Si ions from DMSNs
incubated with hBMS (human bone marrow stromal) cells promotes osteogenesis. The reason was attributed to the biodegradability of DMSNs which results in Si sustained release. In another
study done by Lei et al. [255], a new hydroxyapatite-DMSNs scaffold was fabricated for bone regeneration purposes. The obtained
results from gene expression including osteopontin (OPN), osteocalcin (OCN), collagen type I alpha 1 (CoL1A1), runt-related
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Fig. 13. A) Enhancement in the HIF-1a and VEGF proteins expression due to the release of dimethyloxalylglycine and Si ions from MSNs [272]. B) H&E staining belongs to calvarial
defect samples (i) treated with HA-DMSN and (ii) blank control [255]. C) FGF-2 release from DMSN-based scaffolds with 5 and 10% FGF-2, soaked in PBS at 37  C for 14 days [256]. D)
(i) Stress-strain curves for the hydrogel containing various amounts of MSNs-OH (0e2.5e5e10 wt %), and (ii) a qualitative image comparing the compression behavior of both MSNbased (left) hydrogel and the pure one (right) [262]. E) (i) Digital photos, and (ii) Cross-sectional SEM images of the electrospun bi-layered vascular scaffold. F) MSN-Ceria
neutralized superoxide anions compared with pure ceria aqueous suspension.

instance, Wang et al. integrated mesoporous silica nanoparticles
with a gelatin hydrogel scaffold. They reported that the micropore
size and the mechanical behavior of the ﬁnal scaffold increased
[261]. In another research, a novel hierarchical hydrogel made of
(poly(ethylene glycol diacrylate)) (PEGDA) and hydroxyl mesoporous silica nanoparticles was developed [262]. The results of the
mechanical evaluation conﬁrmed that the stress of breaking of the
hydrogel containing 10% mesoporous silica nanoparticles was
approximately ten-fold stronger than that of the pure hydrogel
(Fig. 9D). Thereby, it can be predicted that DMSN, due to their
higher surface area, can depict better efﬁcacy in scaffold improvement. For example, the addition of DMSNs improved the mechanical behavior of hydrogels without affecting permeability or
rigidity. It was also shown that a potent interaction occurs between
the polymer matrix of polyacrylamide and DMSNs [263]. In another
study, DMSNs were embedded in polyethylene glycol dimethacrylate hydrogel to boost biological activity and mechanical behavior.
Results revealed that the presence of DMSNs was beneﬁcial to
promote elastic modulus, and cell viability and act as biomolecule
carriers [264].

transcription factor 2 (RUNX2), and integrin-binding sialoprotein
(IBSP) indicated the improved osteogenic potential of the scaffold.
In vivo studies showed that the scaffold resulted in more bone
formation after four weeks (Fig. 13B). In another research, ﬁbroblast
growth factor-2 (FGF-2) was loaded onto mesoporous calcium silicate NPs as DMSN and embedded in a PCL-based scaffold [256].
The authors found that DMSN gradually delivered FGF-2 during
scaffold degradation, affecting osteogenesis differentiation and
proliferation of HWJMSCs (human Wharton's jelly mesenchymal
stem cells) (Fig. 13C).
5.3.2. Scaffold improvement
Apart from employing DMSNs and the scaffold to deliver
bioactive factors during tissue regeneration, the presence of DMSNs
also showed their effect on scaffold properties. Apart from the
technique of scaffold fabrication such as 3D bioprinting and electrospinning, DMSNs showed their potential to positively affecting
the mechanical degradation, cell attachment and proliferation, and
porosity of the ﬁnal scaffold [257e260]. Such an improvement was
carried out previously using mesoporous silica nanoparticles. For

22

S. Malekmohammadi, R.U.R. Mohammed, H. Samadian et al.

Materials Today Chemistry 26 (2022) 101144

Liu et al. [47] synthesized DMSNs with a particle size
(156 ± 11 nm), an average pore size of 22 nm, a large surface area of
637 m2 g1, and a high pore volume of 3.08 cm3 g1 for delivering
foot-and-mouth disease virus-like particles (FMD VLPs) protein and
bovine serum albumin (BSA). The results showed that the synthesized DMSNs exhibited excellent protein loading capacity, good
biocompatibility and hemocompatibility, and efﬁcient cellular uptake. The immunization and adjuvant effect on guinea pigs showed
that the synthesized DMSNs induced humoral immune response
and protection against FMDV infection.
Certain studies exploring the effect of the spiky and rough surface of DMSNs found that the surface topology of DMSNs is a critical
feature that improved the loading of smaller NPs within the principal structure [278]. In one such study, DMSNs were synthesized to
evaluate their antibacterial properties. In vitro results revealed that
the DMSNs caused effective inhibition of E. coli and S. aureus survival. These results are crucial as they pave the way for the design of
efﬁcient antibacterial agents. Beitzinger et al. isolated a microbial
peptide named NapFab from bronchoalveolar lavage and optimized
it to improve solubility in an aqueous solution and increase the
positive charge to support the interaction with the negatively
charged mycobacterial cell wall. The peptide was loaded into a
DMSN carrier and administered to Mycobacterium tuberculosis
(Mtb) in vitro. The antimycobacterial property of NapFab was
signiﬁcantly enhanced when encapsulated compared to free NapFab. Moreover, Mtb-infected macrophages incubated with NapFabDMSNs showed an accumulation of DMSNs in the early and late
endosomes, showing the effective peptide transport in the cells and
thereby efﬁciently killing Mtb [279].
For inﬂammation, DMSNs have successfully been used to codeliver ibuprofen (IBU) and BSA (as a protein model) using
DMSNs modiﬁed with amino groups in the inner pores [23]. In the
case of psoriasis, an inﬂammatory skin disorder, Mo et al. used
Erianin-loaded DMSNs to reduce keratinocyte proliferation. Erianin
is a potent inhibitor of keratinocyte proliferation and is also known
to suppress tumor growth angiogenesis [280]. In this study,
Erianin-loaded DMSNs showed a stronger anti-proliferative and
pro-apoptotic effect than free Erianin in HaCaT cells. Moreover,
when DMSNs were embedded in a hydrogel, the drug retention in
porcine skin was better than only Erianin-loaded hydrogels.
Moreover, the DMSNs showed pore-size-dependent anti-proliferative and anti-apoptotic effects against cells via the mitochondrial
signaling pathway. Such DMSN systems can be used for the treatment of keratinocyte-related diseases [281]. Besides, DMSNs have
shown effectiveness in arthritis therapy. In vivo administration of Spropargyl-cysteine (SPRC)-loaded DMSNs suppressed LPS-induced
pro-inﬂammatory cytokines in a rat model of autoimmune arthritis.
The DMSNs were designed to increase the expression of cystathionine ɣ-lyase, an enzyme that produces H2S. The administration of the particles exerted anti-inﬂammatory properties. The t1/2
of SRPC improved drastically to 17.1 h, compared to only 1.6 h for
the free-SPRC group. Moreover, DMSNs did not induce any tissue
damage and had a low toxicity. With a pore size of 10 nm, DMSNs
were shown to be favorable and biocompatible for countering
inﬂammation in arthritic rats [282]. Besides, DMSNs can be utilized
as carriers of unstable products like antioxidants. For instance, due
to the pronounced properties of 5-HM (5-hydroxymethylfurfural)
on skin treatments, it has gained great attention in skin disorder
therapies and cosmetic products. 5-HM can directly be applied to
the skin, however, rapidly loses its bioactivity. The tunable characteristics of DMSNs, make these nanocarriers a good candidate for
directly delivering the 5-HM to the skin [100].
Macrophages can be divided into several subtypes; they
contribute to inﬂammation, tissue damage, regenerative medicine,
and tissue remodeling [283]. The M1 type (“classically activated”)

5.3.3. Vascular tissue engineering
Other studies reporting the role of DMSNs in TE focused on
vascular TE and the angiogenesis activity of DMSNs. DMSNs show
their ability to improve revascularization during TE by carrying
speciﬁc cargoes and anticoagulants [265,266]. Guo and colleagues
[265] fabricated an electrospun bi-layered tubular scaffold as an
implant for blood vessel TE (Fig. 13E). The implant contained
DMSNs that were used as a carrier of salvianolic acid (10%). The
authors found that the presence of DMSNs decreased the elastic
modulus compared with the DMSN-free scaffold. In a similar study
in 2017, Wu et al. [239] used heparin-loaded DMSNs embedded in a
silicon substrate to promote anticoagulation. The scaffold containing DMSNs displayed notable blood compatibility, and no blood
coagulation or platelet adhesion was observed.
5.3.4. Wound healing
To accelerate the process of wound healing, tissue function recovery, protection against inﬂammation, and prevention of infections are mandatory [267e269]. DMSNs can be used as a potent
growth factor carrier, and in addition, their presence can help cell
adhesion. Scientists reported employing DMSNs in wound healing
and skin tissue regeneration. For instance, in 2018, Wu and his
colleagues ﬁrst coated ceria NPs on the surface of DMSNs, and the
ﬁnal nanocomposite was directly employed for wound healing
[270]. The authors claimed that this nanocomposite could play a
vital role as ROS-scavenger. In fact, high adhesion to the tissue and
restriction of ROS exacerbation was reported as distinguishing
features of the DMSNs-based nanocomposite. Considering inﬂammation during the wound healing process, Pan and his colleagues
also used DMSNs directly to the wound area on the rat's back [271].
Results showed that DMSNs were a versatile and convenient adhesive that helped wound closure and inhibited inﬂammation. It is
hypothesized that embedding the drug-loaded DMSNs in
biopolymeric-based wound dressing can promote the rate of
wound healing and skin reconstruction due to its potential for
sustained release, regulating inﬂammation, and cell attachment
and proliferation.
5.4. Antimicrobial, infection, and anti-inﬂammatory therapy
The large surface-volume ratio of NPs allows for greater drug
loading capacity and better contact with microbe surfaces to
develop antimicrobial therapies [273]. Moreover, NPs can increase
the accumulation of the delivered antibacterial cargo at the site of
the disease while minimizing off-target side effects [274,275].
Wang et al. synthesized dendritic ﬁbrous silica NPs (DFSNs) that
imparted antireﬂective and antibacterial properties in coatings. In
this study, DFNs were coated with well-dispersed Ag NPs onto the
surface of poly(methyl methacrylate) (PMMA) polymeric glass via
organic vapor treatment. The PMMA slide with the nanocoating
showed an 80% efﬁciency in killing bacteria (Staphylococcus aureus
and Escherichia coli) [276]. DMSNs have been used to encapsulate
large enzymes that have antimicrobial properties [277]. Also,
compared to traditional mesoporous NPs with a smooth surface,
DMSNs show a better drug-delivery efﬁcacy due to enhanced
adhesion to bacterial cell membranes by their dendritic structure
[277]. Wang et al. showed that DMSNs with a pore size of 22 nm
loaded with lysozyme show prolonged inhibition towards E. coli, in
which the lysozyme had a sustained release pattern [277]. Vaccinations for diseases like foot-and-mouth disease can also be
formulated using DMSNs [19]. In the study by Liu et al., DMSNs with
large center-radial pores were prepared for macromolecular protein loading and delivery. The DMSNs were used as nanocarriers for
bovine-serum albumin and foot-and-mouth disease virus-likeparticles.
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associated with physicochemical properties, such as high zeta potential, shape, and size. For example, zeta potentials higher than
30 mV can damage cell membranes. Also, small NPs (less than
5 nm) can lead to genotoxicity in cells by disrupting various biological structures such as focal adhesion proteins (FAP) or interacting with transcription factors that cause tumorigenesis
mutations. In addition to these two main toxic mechanisms, other
routes have been discovered regarding the toxicity caused by NPs.
For instance, an important issue is the leaking of toxic ions or
molecules that formed the NP after degradation in endo/lysosomal
compartments. This cytotoxicity strongly depends on the composition of NP.
The common examination for evaluation of nano-based materials biocompatibility is a hemolysis test [288]. According to the
ISO/TR7405 standard, the maximum acceptable rate of hemolysis
risk for any formulation should be under 5% [227]. In the case of
DMSNs, it was demonstrated that manipulating the structure with
certain compounds can increase their biocompatibility. For
instance, Ca@DMSNs-FA displayed better hemocompatibility than
pristine DMSNs at high concentrations due to the binding of the
silanol group (SieOH) of DMSNs with the phosphatidylcholine-rich
RBC membrane [227]. For instance, stellated ﬁbrous silica nanospheres (a type of DMSNs) did not show clear acute toxicity in vivo
even up to seven days after administration [289].
Another safety issue is related to the possible accumulation of
nanoparticles in the body. As a result, when designing NPs, one
must carefully consider their application and excretion method.
The excretion of NPs from the body occurred in two ways. NPs with
a molecular weight (MW) less than 5.5 kDa or 10 nm in size are
ﬁltered from the kidneys. NPs above these amounts are mainly
removed from the hepatobiliary pathway [reference]. In this case,
NPs are collected by the RES system and delivered to hepatocyte
cells, and ﬁnally excreted in the feces through conjugation with
bilirubin. This pathway is slower compared to renal clearance. In
the case of mesoporous silica materials, recent studies have
demonstrated the biodegradability of these materials and their
excretion through the renal pathway. It is well established that
mesoporous silica metabolizes to orthosilicic acid (Si(OH)4), which
is well-tolerated by the body and ﬁnally eliminated by urine [73].
Besides, some studies showed that silica-based nanoparticles could
also be excreted in a lower proportion by the hepatobiliary route.
One critical factor that profoundly affects silica-based nanoparticles' safety and thus clearance is their porous structure. The
biphasic stratiﬁcation approach in the synthesis of DMNS causes
better degradability which is another crucial factor in the safety of
DMNSs [31]. Besides, the morphology of nanoparticles can also be a
key factor to improve their biocompatibility. For instance, the headtail asymmetrical structure of silica NPs shows higher hemocompatibility compared to symmetrical ones [222]. The physicochemical properties of the nanoparticles are critical factors to
achieve biocompatibility. They determine their pharmacokinetics
and biodistribution proﬁle in the body, which ﬁnally determines
the clearance process. More research efforts are still needed to
elucidate the biocompatibility and clearance of the nanoparticles to
bring these promising delivery systems from bench to bedside.

macrophages are related to inﬂammation and tissue damage. In
contrast, the M2 type (“alternatively activated”) macrophages are
involved in tissue remodeling and regeneration [227]. The
switching of M1 to M2 macrophages has an undeniable role in
restoring tissue homeostasis after injury or infection [284].
Recently, it has been shown that diabetes could be worsened by M1
but amended by M2 macrophages [285]. IL-4 is an antiinﬂammatory cytokine with type-switching of M1 to M2 macrophage capability, so local delivery of this cytokine can be a suitable
choice in dealing with diabetes. DMSNs were used to load IL-4.
These NPs did not induce inﬂammatory responses, which is vital
for the polarization of anti-inﬂammatory M2 macrophages.
5.5. Theranostics
Theranostic is a term used to integrate imaging and therapeutic
technologies simultaneously [286]. The use of NPs-based contrast
agents has numerous advantages over conventional contrast
agents, including the ability to bind ligands for targeting diseased
sites, signals ampliﬁcation due to high loading, reducing the
toxicity of some contrast agents, follow up the treatment efﬁcacy,
and use them as theranostic agents. Some NPs used as contrast
agents and can convert one type of energy into another one. For
example, gold NPs can transform near-infrared irradiation into
heat. Subsequently, these heat propagated vibrations can be
detected by ultrasound equipment as a photoacoustic imaging
system [287]. The main advantage of the theranostic system is that
it enables monitoring therapeutic efﬁcacy by following the
diseased site even for several hours to several days after treatment.
As previously mentioned, the high surface area of the DMSNs gives
them unique characteristics to act as carriers and use in various
applications. For example, DMSNs were chosen to load radio-dense
metals like gold (Au) and tantalum oxide (TaOx). The gold and
tantalum oxide-loaded DMSNs were then administered for imaging
and treating ovarian cancer. In the result obtained by KashﬁSadabad et al. [103], Au and TaOx DMSNs were injected intraperitoneally in a mouse model of ovarian cancer. Au and TaOx DMSNs
accumulated and penetrated the cancerous organ and acted as an
improved contrast agent resulting in higher-quality CT scan images.
Combining DMSNs with a relatively new non-invasive strategy
like PDT can enhance the anti-tumor activity of therapeutic agents.
Nevertheless, the efﬁciency of PDT is limited by the hypoxia medium of TME. Researchers have recently developed a multifunctional nano theranostic system based on DMSNs containing upconversion NP (UCNPs) to create trimodal (UCL/MRI/CT) bioimaging and synergistic CDT/PDT/gas strategy for cancer therapy.
These NP were composed of copper peroxide nanodots, chlorin e6
(Ce6),
and
polyethylene
glycol
(PEG)
(UCNPs@dMSNSNO@CuO2eCe6-PEG) [108]. After endocytosis of the nanocomposites mentioned above, nanodots are fragmented in the
acidic environment of TME, permitting the propagation of copper
ions in the cells and subsequent production of H2O2 to achieve an
efﬁcient therapy [108].
6. Safety and toxicity
As discussed above, DMSNs are promising nanoplatforms for
developing both imaging and therapeutic systems. However, safety
and toxicity issues are still a concern in the biomedical application
of nanoparticles. Several studies conﬁrmed the biocompatibility of
silica NPs, their possible toxicity and severity controlled by several
factors in which the dose and administration exposure play a
crucial role. The cytotoxicity of nanomaterials can be divided into
two categories: 1) Toxicity due to the remnant solvents, surfactants,
and chemicals used in the manufacturing of NPs. 2) Toxicity is

7. Conclusions and future directions
The large pore size of DMSNs makes them an excellent candidate for theranostics due to their central-radial pore channels and
highly accessible internal surface. These features enable the utilization of DMSNs as a next-generation multifunctional nanocarrier
with a wide range of payloads and diverse functionalities. Moreover, DMSNs have better biodegradability and safety proﬁles
compared to other silica nanoparticles due to the dendritic
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morphology that facilitates biodegradation. The above properties
extend the usability of DMSNs to antimicrobial therapies, vaccine
development, tissue engineering, and immunotherapeutics. We
elucidated the recent progress made on biomedical applications of
DMSNs in various areas with a focus on anti-tumor therapies along
with a comprehensive review of the synthesis strategies and
characterization. With increasing interest in DMSN synthesis and
application, this review serves as an essential tool and a short guide
to enable future researchers to optimize the synthesis mechanism
of DMSNs and design novel therapies for life-threatening conditions. Despite the advances in the development of DMSNs, the
research on their application is still in an early stage and much
more research is expected in a near future.
Future research needs to be focused on exploiting the potential
of these DMSNs in different biomedical applications. Besides, the
structure of DMSNs facilitates the development of mesoporous
silica materials with faster degradation rates. Although the FDA
recognizes silica, and its related degradation products, as “generally
recognized as safe” (GRAS), a slower degradability in the body could
lead to bioaccumulation and thus long-term toxicity resulting in
diseases. Thus, the development of more easily clearable nanoparticles as DMSNs would be beneﬁcial for achieving a clinical
translation. Nevertheless, many efforts are still needed, and more
studies evaluating the safety and fate of these materials at a preclinical level are required. Even though some challenges have still
to be overcome, all the ﬁndings highlighted in this review suggested the suitability of DMSNs for further advanced applications in
biomedicine. The beneﬁt-to-risk ratio must be evaluated for each
newly designed nanomaterial as well as consider the ﬁnal
biomedical application. Several new advances in the ﬁeld of DMSNs
can be expected in the near future, and we hope this review has
given insights into the rational design of DMSNs nanoparticles and
their future application.
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